{"id": 6, "data": "baseline d-dimer levels were elevated in 19 (59%) cases.", "label": [[9, 16, "BIOMARKER"]]}
{"id": 12, "data": "© 2017 s. karger ag, basel introduction during the last 10 years a number of case reports and case series along with 3 phase iii studies [1-3] and a reallife study [4] have shown that the humanised monoclonal anti-ige antibody omalizumab is effective in patients with severe chronic spontaneous urticaria (csu) not responding to antihistamines at higher than licensed doses.", "label": [[209, 217, "TREATMENT"], [227, 237, "TREATMENT"], [268, 310, "DISEASE"], [329, 343, "TREATMENT"]]}
{"id": 18, "data": "in the present study, we measured d-dimer plasma levels before and after the first administration of omalizumab in patients with severe csu and analysed the results in the light of clinical response to the treatment.", "label": [[34, 41, "BIOMARKER"], [101, 111, "TREATMENT"], [129, 139, "DISEASE"]]}
{"id": 30, "data": "the crp plasma concentration was measured using a sandwich enzyme immunoassay d-dimer response to omalizumab in csu (zymutest crp, hyphen biomed).", "label": [[4, 7, "BIOMARKER"], [78, 85, "BIOMARKER"], [98, 108, "TREATMENT"], [112, 115, "DISEASE"], [117, 129, "DIAGNOSTIC"]]}
{"id": 36, "data": "the data were analysed using the spss pc statistical package, version 22.00 (ibm spss inc., chicago, il, usa).", "label": []}
{"id": 48, "data": "demographic, clinical, and laboratory features of 32 patients with csu undergoing omalizumab treatment pasex age, disease ae aana — crp, tient years _ duration, tpo ug/ml no. months 1 m 77 36 0 1 1 11.90 2 f 47 18 1 1 1 14.20 3 m 47 9 0 0 0 7.80 4 m 65 18 1 0 0 12.80 5", "label": [[67, 70, "DISEASE"], [82, 92, "TREATMENT"], [132, 135, "BIOMARKER"]]}
{"id": 54, "data": "0.76 21 f 50 131 1 1 1 1.00 22 f 70 36 0 0 0 0.65 23 f 37 60 0 0 0 1.17 24 m 51 18 0 0 0 13.69 25 f 60 33 1 0 0 8.87 26 f 21 46 0 0 0 4.78 27 f 31 39 0 0 0 0.48 28 m 54 19 0 0 1 1.58 29 f 15 28 0 0 1 0.23 30 m 59 62 0 0 0 3.48 31 f 39 47 0 0 0 12.30 32 m 69 66 1 0 0 13.63 nsaid previous response latency, d-dimer, d-dimer, treatments days baseline, treatment, ng/ml ng/ml 0 cs, cya 0 - 808 847 0 cs, cya 4 3 1,200 140 0 cs, cya 4 3 787 170 1 cs 4 2 1,815 657 0 none 4 3 260 240 0 cs, cya 4 4 670 194 0 cs 0 - 805 3,446 1 cs 4 4 280 237 0 cs 0 - 1,080 1,271 0 cs 4 5 3,929 419 0 cs 4 4 320 260 0 cs, cya 3 7 280 210 0 cs, cya 4 5 563 144 0 none 0 - 1,800 1,880 0 cya 4 4 1,428 184 0 cs 0 - 230 240 0 cs 4 1 564 159 1 cs 4 2 2,096 200 0 cs 4 7 260 220 0 none 3 10 180 160 0 cs, cya 3 6 194 168 0 cs 2 7 210 187 0 none 3 4 912 306 0 cs 4 1 1,330 117 0 cs, anti-h2 3 5 1,296 431 0 cs, anti-h2 4 1 348 230 0 none 0 - 554 656 0 cs 4 1 234 103 0 none 4 1 288 84 0 none 3 1 752 428 0 none 0 - 234 268 1 cs, anti-h2 4 1 5,403 631 ae, angioedema; a-tpo, anti-thyroid peroxidase antibodies; ana, anti-nuclear antibodies; crp, c-reactive protein; nsaid, nonsteroidal anti-inflammatory drug-induced exacerbation (0, absent; 1, present); cs, corticosteroids; cya, cyclosporin a; anti-h2, h2 antihistamines; response, response to omalizumab (0, uas-7 unchanged; 1, uas-7 reduced to 22-28; 2, uas 7 reduced to 15-21; 3, uas-7 reduced to 8-14; 4, uas-7 reduced to 0-7).", "label": [[273, 278, "TREATMENT"], [306, 313, "BIOMARKER"], [315, 322, "BIOMARKER"], [397, 399, "TREATMENT"], [401, 404, "TREATMENT"], [421, 423, "TREATMENT"], [425, 428, "TREATMENT"], [443, 445, "TREATMENT"], [481, 483, "TREATMENT"], [485, 488, "TREATMENT"], [503, 505, "TREATMENT"], [522, 524, "TREATMENT"], [539, 541, "TREATMENT"], [560, 562, "TREATMENT"], [579, 581, "TREATMENT"], [596, 598, "TREATMENT"], [600, 603, "TREATMENT"], [618, 620, "TREATMENT"], [622, 625, "TREATMENT"], [663, 666, "TREATMENT"], [683, 685, "TREATMENT"], [700, 702, "TREATMENT"], [717, 719, "TREATMENT"], [736, 738, "TREATMENT"], [773, 775, "TREATMENT"], [777, 780, "TREATMENT"], [795, 797, "TREATMENT"], [831, 833, "TREATMENT"], [850, 852, "TREATMENT"], [854, 861, "TREATMENT"], [878, 880, "TREATMENT"], [882, 889, "TREATMENT"], [923, 925, "TREATMENT"], [996, 998, "TREATMENT"], [1000, 1007, "TREATMENT"], [1022, 1024, "DISEASE"], [1026, 1036, "DISEASE"], [1038, 1043, "BIOMARKER"], [1045, 1079, "BIOMARKER"], [1081, 1084, "BIOMARKER"], [1086, 1109, "BIOMARKER"], [1111, 1114, "BIOMARKER"], [1116, 1134, "BIOMARKER"], [1136, 1141, "TREATMENT"], [1143, 1199, "DISEASE"], [1225, 1227, "TREATMENT"], [1229, 1244, "TREATMENT"], [1246, 1249, "TREATMENT"], [1251, 1264, "TREATMENT"], [1266, 1273, "TREATMENT"], [1275, 1292, "TREATMENT"], [1316, 1326, "TREATMENT"], [1331, 1336, "BIOMARKER"], [1351, 1356, "BIOMARKER"], [1378, 1383, "BIOMARKER"], [1405, 1410, "BIOMARKER"], [1431, 1436, "BIOMARKER"], [375, 377, "TREATMENT"], [379, 382, "TREATMENT"]]}
{"id": 60, "data": "such effects require 3-4 weeks to occur, at least on mast cells, which is far longer than the few days frequently needed to appreciate a asero/marzano/ferrucci/cugno national univ. of singapore 137.132.123.69 - 4/10/2017 3:16:26 am downloaded by: 6,000 5 ca ° 3s 3s 1 d-dimer, ng/ml l fig.", "label": [[53, 63, "BIOMARKER"], [135, 142, "PERSON"], [143, 150, "PERSON"], [151, 159, "PERSON"], [160, 165, "PERSON"], [268, 275, "BIOMARKER"]]}
{"id": 72, "data": "one possibility is that the activation of the coagulation cascade non-specifically mirrors the general inflammatory state that underlies the disease.", "label": [[46, 65, "DISEASE"]]}
{"id": 78, "data": "however, in those showing elevated baseline d-dimer levels the clinical response to the drug was paralleled by a rapid and impressive decrease of coagulation activation [9], whereas in treatment failures d-dimer levels remained unchanged or even increased during the treatment.", "label": [[44, 51, "BIOMARKER"], [146, 157, "DISEASE"], [204, 211, "BIOMARKER"]]}
{"id": 84, "data": "int arch allergy immunol 2017;172:40-44 43 doi: 10.1159/000453453 017 3:16:26 am references saini s, rosen ke, hsieh hj, wong da, conner e, kaplan a, spector s, maurer m: a randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with h1-antihistamine-refractory chronic idiopathic urticaria.", "label": [[92, 99, "PERSON"], [101, 109, "PERSON"], [111, 119, "PERSON"], [121, 128, "PERSON"], [130, 138, "PERSON"], [140, 148, "PERSON"], [150, 159, "PERSON"], [161, 169, "PERSON"], [239, 249, "TREATMENT"], [185, 192, "TREATMENT"], [267, 323, "DISEASE"]]}
{"id": 90, "data": "int arch allergy immunol 2016;169:121-124.", "label": []}
{"id": 96, "data": "ann allergy asthma immunol 2014;112:170-174.", "label": [[4, 11, "DISEASE"], [12, 18, "DISEASE"]]}
{"id": 102, "data": "allergy 2011;66:428-— 433.", "label": [[0, 7, "DISEASE"]]}
{"id": 108, "data": "44 int arch allergy immunol 2017;172:40-44 doi: 10.1159/000453453 13 14 15 16 17 18 zuberbier t, aberer w, asero r, bindslevjensen c, brzoza z, canonica gw, church mk, ensina lf, giménez-arnau a, godse k, gongalo m, grattan c, hebert j, hide m, kaplan a, kapp a, abdul latiff ah, mathelierfusade p, metz m, nast a, saini ss, sanchezborges m, schmid-grendelmeier p, simons fe, staubach p, sussman g, toubi e, vena ga, wedi b, zhu xj, maurer m: the eaaci/ ga?len/edf/wao guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update.", "label": [[12, 19, "DISEASE"], [84, 95, "PERSON"], [97, 105, "PERSON"], [107, 114, "PERSON"], [116, 132, "PERSON"], [134, 142, "PERSON"], [144, 155, "PERSON"], [157, 166, "PERSON"], [168, 177, "PERSON"], [179, 194, "PERSON"], [196, 203, "PERSON"], [205, 214, "PERSON"], [216, 225, "PERSON"], [227, 235, "PERSON"], [237, 243, "PERSON"], [245, 253, "PERSON"], [255, 261, "PERSON"], [263, 278, "PERSON"], [280, 297, "PERSON"], [299, 305, "PERSON"], [307, 313, "PERSON"], [315, 323, "PERSON"], [325, 340, "PERSON"], [342, 363, "PERSON"], [365, 374, "PERSON"], [376, 386, "PERSON"], [388, 397, "PERSON"], [399, 406, "PERSON"], [408, 415, "PERSON"], [417, 423, "PERSON"], [425, 431, "PERSON"], [433, 441, "PERSON"], [544, 553, "DISEASE"]]}
{"id": 114, "data": "b, gumuslu s: d-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment.", "label": [[3, 12, "PERSON"], [14, 21, "BIOMARKER"], [42, 64, "DISEASE"], [69, 86, "DISEASE"], [105, 115, "TREATMENT"]]}
{"id": 120, "data": "int arch allergy immunol 2009;", "label": [[9, 16, "DISEASE"]]}
{"id": 126, "data": "author manuscript; available in pmc 2017 may 01. published in final edited form as: j allergy clin immunol pract.", "label": [[86, 93, "DISEASE"]]}
{"id": 132, "data": "igg autoantibodies to ige or to the high-affinity ige receptor (fcerd) have been directly detected in ~40-50% of cu patients.2 while of interest, identifying these antibodies is laborious and not fully validated, therefore, numerous surrogate assays have been developed.", "label": [[0, 18, "BIOMARKER"], [22, 25, "BIOMARKER"], [50, 53, "BIOMARKER"], [64, 69, "BIOMARKER"], [113, 115, "DISEASE"]]}
{"id": 138, "data": "(see yasnowsky et al.", "label": [[5, 14, "PERSON"]]}
{"id": 150, "data": "omalizumab, a humanized anti-[ge monoclonal antibody, has been approved for the treatment of cu.", "label": [[0, 10, "TREATMENT"], [93, 95, "DISEASE"]]}
{"id": 156, "data": "basophil cd203cupregulating activity was obtained in all subjects prior to omalizumab administration (national jewish health advance diagnostic laboratories, denver co).", "label": [[0, 8, "BIOMARKER"], [75, 85, "TREATMENT"], [9, 17, "BIOMARKER"]]}
{"id": 162, "data": "67-9, of the 18 subjects demonstrating cd203c-upregulating activity, only 9 (50%) had clinical improvement with omalizumab (figure i).", "label": [[39, 45, "BIOMARKER"], [112, 122, "TREATMENT"]]}
{"id": 168, "data": "omalizumab binds to free ige in the circulation and therefore prevents ige from binding to mast cells and basophils®.", "label": [[0, 10, "TREATMENT"], [25, 28, "BIOMARKER"], [71, 74, "BIOMARKER"], [91, 101, "BIOMARKER"], [106, 115, "BIOMARKER"]]}
{"id": 174, "data": "therefore, one mechanism of action for omalizumab in cu may be through down-regulation of the antigenic target of the autoantibodies.’ however, in one — albeit modestly sized — study this down-regulation of fceri expression did not extend to mast cells, the presumed source of disease in cu,° questioning the role for this mechanism in cu.", "label": [[39, 49, "TREATMENT"], [53, 55, "DISEASE"], [207, 212, "BIOMARKER"], [242, 252, "BIOMARKER"], [288, 290, "DISEASE"], [336, 338, "DISEASE"]]}
{"id": 192, "data": "guttmanyassky e, bergman r, maor c, mamorsky m, pollack s,", "label": [[0, 15, "PERSON"], [17, 26, "PERSON"], [28, 34, "PERSON"], [36, 46, "PERSON"], [48, 57, "PERSON"]]}
{"id": 198, "data": "[pubmed: 19131947] 5.", "label": []}
{"id": 216, "data": "2011; 6:e14794.", "label": []}
{"id": 222, "data": "metz m, ohanyan t, church mk, maurer m. omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.", "label": [[0, 6, "PERSON"], [8, 17, "PERSON"], [19, 28, "PERSON"], [30, 36, "PERSON"], [40, 50, "TREATMENT"], [116, 133, "DISEASE"]]}
{"id": 228, "data": "1duosnueyy souiny 1duosnuey\\ soulny palacios et al.", "label": [[36, 44, "PERSON"]]}
{"id": 234, "data": "1duosnueyy souiny 1duosnuey\\ soulny palacios et al.", "label": [[36, 44, "PERSON"]]}
{"id": 240, "data": "1duosnuey\\ jouiny 1duosnuey\\ soulny 1duosnueyy souiny 1diuosnuey\\ soulny palacios et al.", "label": [[73, 81, "PERSON"]]}
{"id": 246, "data": "author manuscript; available in pmc 2017 may 01.", "label": []}
{"id": 252, "data": "cristoforo incorvaia allergy/pulmonary rehabilitation, icp hospital, via bignami |, 20126 milan, italy tel +39 02 5799 3289 fax +39 02 5799 3759 email cristoforo.incorvaia@gmail.com this article was published in the following dove press journal: drug design, development and therapy 7 february 2014 number of times this article has been viewed abstract: a large number of trials show that the anti-immunoglobulin (ig) e antibody omalizumab is very effective in patients with severe allergic asthma.", "label": [[393, 419, "BIOMARKER"], [429, 439, "TREATMENT"], [0, 20, "PERSON"], [475, 497, "DISEASE"]]}
{"id": 258, "data": "concerning the former, clinical efficacy has been observed in rhinitis, allergic bronchopulmonary aspergillosis, latex allergy, atopic dermatitis, allergic urticaria, and anaphylaxis.", "label": [[62, 70, "DISEASE"], [72, 111, "DISEASE"], [113, 126, "DISEASE"], [128, 145, "DISEASE"], [147, 165, "DISEASE"], [171, 182, "DISEASE"]]}
{"id": 264, "data": "ige plays a central role in the pathophysiology of allergic disease. once ige reaches the bloodstream, it binds to the high-affinity ige receptor (fceri) on the surface of mast cells and basophils and, upon contact with a specific allergen, induces the release of pharmacologically active mediators stored in the granules of these cells, resulting in clinical manifestations of type i hypersensitivity.’", "label": [[0, 3, "BIOMARKER"], [74, 77, "BIOMARKER"], [133, 136, "BIOMARKER"], [147, 152, "BIOMARKER"], [172, 182, "BIOMARKER"], [187, 196, "BIOMARKER"], [378, 401, "DISEASE"]]}
{"id": 270, "data": "information on how to request permission may be found at: http://www.dovepress.com/permissions.php incorvaia", "label": [[99, 108, "PERSON"]]}
{"id": 276, "data": "adult and adolescent patients with ige below 76 iu/ml and children with ige below 200 iu/ml must have reactivity (rast) to a perennial allergen before starting therapy (tables 1-3).", "label": [[35, 38, "BIOMARKER"], [72, 75, "BIOMARKER"]]}
{"id": 288, "data": "this rate is similar to the incidence of anaphylactic reactions for other drugs, such as oral penicillins, aspirin, and nonsteroidal anti-inflammatory drugs,’ as well as to the incidence and prevalence of anaphylaxis reported in the general omalizumab-free population (about 0.05%-2%).", "label": [[89, 105, "TREATMENT"], [107, 114, "TREATMENT"], [120, 156, "TREATMENT"], [205, 216, "DISEASE"], [241, 251, "TREATMENT"]]}
{"id": 294, "data": "a significant number of patients were able to reduce their dose of inhaled steroids, which are the mainstay of asthma therapy, by more than 50% submit your manuscript 198 dove drug design, development and therapy 2014:8 dove e-switch 7 bronchoconstriction > lor-vaek-1i(e)", "label": [[67, 83, "TREATMENT"], [111, 117, "DISEASE"], [236, 255, "DISEASE"]]}
{"id": 306, "data": ">1.2 ml =maximum delivered volume per vial (xolair 150 mg). ‘or use 0.6 ml from a 150 mg vial.", "label": [[44, 50, "TREATMENT"]]}
{"id": 312, "data": "** this accounts for a possible role of ige in nonatopic asthma.", "label": [[40, 43, "BIOMARKER"], [47, 63, "DISEASE"]]}
{"id": 318, "data": "™ further support for these additional effects of omalizumab has been provided by studies showing that its action extends to the complex signaling mechanism, leading to activation of effector cells and release of mediators.", "label": [[50, 60, "TREATMENT"], [183, 197, "BIOMARKER"]]}
{"id": 330, "data": "the outcome of the significant reduction in asthma exacerbations is in agreement with our current practice; in our patients, the mean numbers of emergency department visits and hospitalizations were found to be 5.6 and 3.2, respectively, before treatment compared with 1.2 and 0.8 after treatment with omalizumab. submit your manuscript 200 dove drug design, development and therapy 2014:8 dove table 3 administration every 2 weeks anti-lge antibody omalizumab body weight (kg) baseline ige >90| >125(iu/ml) >", "label": [[44, 64, "DISEASE"], [302, 312, "TREATMENT"], [432, 440, "TREATMENT"], [450, 460, "TREATMENT"], [487, 490, "BIOMARKER"]]}
{"id": 336, "data": "* a significant mean reduction in thickness of the reticular basement membrane and eosinophil infiltration in bronchial biopsies from patients with severe persistent allergic asthma was recorded after one year of omalizumab treatment using light microscopic image analysis.", "label": [[83, 93, "BIOMARKER"], [110, 128, "DIAGNOSTIC"], [213, 223, "TREATMENT"], [240, 272, "DIAGNOSTIC"], [148, 181, "DISEASE"]]}
{"id": 342, "data": "s. aureus, the enterotoxins of which act as superantigens, also plays an important role in this DISEASE.", "label": [[0, 9, "PERSON"]]}
{"id": 348, "data": "allergic bronchopulmonary aspergillosis develops in a small proportion of patients with asthma, but patients with cystic fibrosis may also be affected, suggesting that intrinsic host defects play a major role in susceptibility to this disease.", "label": [[0, 39, "DISEASE"], [88, 94, "DISEASE"], [114, 129, "DISEASE"]]}
{"id": 354, "data": "all patients showed significant improvement in their clinical scores for atopic dermatitis.", "label": [[73, 90, "DISEASE"]]}
{"id": 360, "data": "therefore, the positive results obtained in this DISEASE were the most surprising: an initial report of complete resolution of a case of cold urticaria with omalizumab*! was followed by therapeutic success in urticaria caused by heat* and dove delayed pressure, as well as in solar and cholinergic® urticaria.", "label": [[139, 153, "DISEASE"], [159, 169, "TREATMENT"], [211, 220, "DISEASE"], [301, 310, "DISEASE"]]}
{"id": 366, "data": "® in a study of autoimmune urticaria not controlled by antihistamines, including 12 patients with positive autologous serum skin and histamine release tests, all patients recetved omalizumab following 4 weeks of treatment with placebo, and showed significant improvement in clinical scores (complete resolution in seven cases), a significant decrease in consumption of drugs used for symptomatic relief, and improvement in quality of life, with only one patient not responding to treatment.”", "label": [[16, 36, "DISEASE"], [55, 69, "TREATMENT"], [107, 128, "DIAGNOSTIC"], [133, 156, "DIAGNOSTIC"], [180, 190, "TREATMENT"], [227, 234, "TREATMENT"], [274, 289, "DIAGNOSTIC"], [480, 489, "TREATMENT"]]}
{"id": 372, "data": "the first two studies reporting clinical efficacy suggested to the authors that omalizumab might inhibit the alleged stimulation of survival and accumulation of mast cells by ige’ and downregulation of the fceri receptor.", "label": [[80, 90, "TREATMENT"], [161, 171, "BIOMARKER"], [175, 178, "BIOMARKER"], [206, 220, "BIOMARKER"]]}
{"id": 378, "data": "*’ a placebo-controlled trial tested the effects of anti-ige therapy on reactions to peanuts, the dominant cause of food-related anaphylaxis in the us.", "label": [[5, 12, "TREATMENT"], [52, 68, "TREATMENT"], [116, 140, "DISEASE"]]}
{"id": 384, "data": "a recent study evaluated the efficacy of omalizumab in 22 patients receiving treatment for asthma who had concomitant food allergy.”", "label": [[41, 51, "TREATMENT"], [91, 97, "DISEASE"], [106, 130, "DISEASE"]]}
{"id": 390, "data": "the oral food challenges and skin prick test titrations were repeated after reduction of basophil histamine release (or at week 8 if basophil histamine release did not decrease) and again at 6 months.", "label": [[4, 24, "DIAGNOSTIC"], [29, 44, "DIAGNOSTIC"], [89, 107, "BIOMARKER"], [133, 151, "BIOMARKER"]]}
{"id": 396, "data": "eosinophilic esophagitis is a disorder of increasing interest in which food allergens, as well as inhaled allergens, play a causative role.’”” in one report, two patients with multiple food allergies and eosinophilic esophagitis were treated with omalizumab and showed significant improvement in symptoms, despite negligible histologic and endoscopic responses.” other disorders there are case reports describing the efficacy of omalizumab in other disorders, including both ige-mediated diseases drug design, development and therapy 2014:8 submit your manuscript 203 dove incorvaia et al and disorders of unknown pathogenesis.", "label": [[0, 24, "DISEASE"], [185, 199, "DISEASE"], [204, 228, "DISEASE"], [247, 257, "TREATMENT"], [296, 304, "DISEASE"], [325, 335, "DISEASE"], [340, 360, "DISEASE"], [429, 439, "TREATMENT"], [475, 496, "DISEASE"], [573, 582, "PERSON"]]}
{"id": 402, "data": "™ once again, omalizumab proved to be effective in disorders unrelated to ige-mediated hypersensitivity, such as interstitial cystitis,* bullous pemphigoid,** chronic rhinosinusitis,*” and aspirinexacerbated respiratory disease.", "label": [[14, 24, "TREATMENT"], [74, 104, "DISEASE"], [113, 134, "DISEASE"], [137, 155, "DISEASE"], [159, 181, "DISEASE"], [189, 227, "DISEASE"]]}
{"id": 408, "data": "the effects of omalizumab in preventing adverse reactions to sit in patients with mastocytosis have already been discussed,® but another area of concern is the safety of sit with bee venom, which is much less well tolerated than vespid venom.”", "label": [[15, 25, "TREATMENT"], [82, 94, "DISEASE"]]}
{"id": 414, "data": "however, use of omalizumab is warranted in patients with asthma that cannot be controlled by standard drug treatment (and thus excluded from sit) and in patients unable to reach the maintenance dose of venom immunotherapy because of repeated adverse reactions.", "label": [[16, 26, "TREATMENT"], [57, 63, "DISEASE"], [202, 221, "TREATMENT"]]}
{"id": 420, "data": "submit your manuscript 204 dove drug design, development and therapy 2014:8 dove acknowledgment the authors thank dr donatella tedeschi and dr alina papetti from the medical department of novartis farma spa, origgio, italy, for their cooperation and for providing figures | and 2.", "label": [[114, 135, "PERSON"], [140, 156, "PERSON"]]}
{"id": 426, "data": "wide l, bennich h, johansson sg.", "label": [[0, 6, "PERSON"], [8, 17, "PERSON"], [19, 31, "PERSON"]]}
{"id": 432, "data": "jw, busse ww, editors.", "label": [[4, 12, "PERSON"]]}
{"id": 450, "data": "corren j, casale tb, lanier b, buhl r, holgate s, jimenez", "label": [[0, 8, "PERSON"], [10, 19, "PERSON"], [21, 29, "PERSON"], [31, 37, "PERSON"], [39, 48, "PERSON"], [50, 57, "PERSON"]]}
{"id": 462, "data": "a. real-life effectiveness of omalizumab in patients with severe persistent allergic (ige-mediated) asthma at a single uk hospital.", "label": [[30, 40, "TREATMENT"], [58, 106, "DISEASE"]]}
{"id": 468, "data": "mauro m, incorvaia c,", "label": [[0, 7, "PERSON"], [9, 20, "PERSON"]]}
{"id": 480, "data": "busse ww, morgan wj, gergen pj, et al.", "label": [[0, 8, "PERSON"], [10, 19, "PERSON"], [21, 30, "PERSON"]]}
{"id": 492, "data": "barnes n, menzies-gow a, mansyr ah, et al.", "label": [[0, 8, "PERSON"], [10, 23, "PERSON"], [25, 34, "PERSON"]]}
{"id": 498, "data": "22.", "label": []}
{"id": 504, "data": "29.", "label": []}
{"id": 510, "data": "38. 39.", "label": []}
{"id": 516, "data": "results from a large cohort of patients with severe uncontrolled asthma. chest.", "label": [[45, 71, "DISEASE"]]}
{"id": 522, "data": "a proof of concept randomized controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma. chest.", "label": [[50, 60, "TREATMENT"], [106, 122, "DISEASE"]]}
{"id": 528, "data": "chem immunol allergy.", "label": [[13, 20, "DISEASE"]]}
{"id": 534, "data": "regulation of syk kinase and fcrbeta expression in human basophils during treatment with omalizumab.", "label": [[14, 24, "BIOMARKER"], [29, 36, "BIOMARKER"], [57, 66, "BIOMARKER"], [89, 99, "TREATMENT"]]}
{"id": 540, "data": "813-815.", "label": []}
{"id": 552, "data": "the costs and consequences of omalizumab in uncontrolled asthma from a usa payer perspective.", "label": [[30, 40, "TREATMENT"], [44, 63, "DISEASE"]]}
{"id": 558, "data": "2012;6:87-95.", "label": []}
{"id": 564, "data": "2012;83:520-528.", "label": []}
{"id": 576, "data": "2009;64: 81-84.", "label": []}
{"id": 582, "data": "2007;21:428-432.", "label": []}
{"id": 588, "data": "successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-ige antibody. thorax.", "label": [[24, 63, "DISEASE"], [69, 98, "TREATMENT"]]}
{"id": 594, "data": "lebecque p, leonard a, argaz m, godding v, pilette c. omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.", "label": [[0, 10, "PERSON"], [12, 21, "PERSON"], [23, 30, "PERSON"], [32, 41, "PERSON"], [54, 64, "TREATMENT"], [86, 125, "DISEASE"], [143, 158, "DISEASE"], [43, 52, "PERSON"]]}
{"id": 600, "data": "collins j, devos g, hudes g, rosenstreich d. allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab.", "label": [[0, 9, "PERSON"], [11, 18, "PERSON"], [20, 27, "PERSON"], [45, 84, "DISEASE"], [124, 134, "TREATMENT"], [29, 43, "PERSON"]]}
{"id": 606, "data": "69.", "label": []}
{"id": 612, "data": "bock sa, munoz-furlong a, sampson ha.", "label": [[0, 7, "PERSON"], [9, 24, "PERSON"], [26, 36, "PERSON"]]}
{"id": 618, "data": "effects of anti-ige therapy in patients with peanut allergy.", "label": [[11, 27, "TREATMENT"], [52, 59, "DISEASE"]]}
{"id": 624, "data": "2008;101:550-s551. warrier p, casale tb. omalizumab in idiopathic anaphylaxis.", "label": [[19, 28, "PERSON"], [30, 39, "PERSON"], [41, 51, "TREATMENT"], [55, 77, "DISEASE"]]}
{"id": 630, "data": "bray sm, fajt ml, petrov aa.", "label": [[0, 7, "PERSON"], [9, 16, "PERSON"], [18, 27, "PERSON"]]}
{"id": 636, "data": "72.", "label": []}
{"id": 642, "data": "2010;10:312-317. of omalizumab in the treatment of atopic dermatitis: a pilot study.", "label": [[20, 30, "TREATMENT"], [51, 68, "DISEASE"]]}
{"id": 648, "data": "heil pm, maurer d, klein b, hultsch t, sting] g. omalizumab therapy proc.", "label": [[0, 7, "PERSON"], [9, 17, "PERSON"], [19, 26, "PERSON"], [28, 37, "PERSON"], [39, 44, "PERSON"], [49, 59, "TREATMENT"]]}
{"id": 654, "data": "2010;8:990-998. omalizumab-treated adults with peanut allergy.", "label": [[16, 26, "TREATMENT"], [54, 61, "DISEASE"]]}
{"id": 660, "data": "2006;117:1415-1418.", "label": []}
{"id": 666, "data": "allergy.", "label": [[0, 7, "DISEASE"]]}
{"id": 672, "data": "gastrointestinal disorders.", "label": [[0, 26, "DISEASE"]]}
{"id": 678, "data": "e, montagni m, olivieri e, rogkakou a, de’ angelis gl, successful treatment of solar urticaria with anti-immunoglobulin e canonica gw. eosinophilic esophagitis: which role for food and therapy.", "label": [[3, 13, "PERSON"], [15, 25, "PERSON"], [27, 37, "PERSON"], [39, 53, "PERSON"], [79, 94, "DISEASE"], [100, 121, "BIOMARKER"], [135, 159, "DISEASE"]]}
{"id": 684, "data": "55.", "label": []}
{"id": 690, "data": "1471-1474.", "label": []}
{"id": 696, "data": "of solar urticaria after omalizumab.", "label": [[3, 18, "DISEASE"], [25, 35, "TREATMENT"]]}
{"id": 702, "data": "leynadier f, doudou o,", "label": [[0, 11, "PERSON"], [13, 21, "PERSON"]]}
{"id": 714, "data": "clinical grading of atopic keratoconjunctivitis.", "label": [[20, 47, "DISEASE"]]}
{"id": 720, "data": "82.", "label": []}
{"id": 726, "data": "ann allergy asthma immunol.", "label": [[4, 11, "DISEASE"], [12, 18, "DISEASE"]]}
{"id": 732, "data": "neukirch c, aubier m. omalizumab for severe atopic of chronic autoimmune urticaria with omalizumab.", "label": [[0, 10, "PERSON"], [22, 32, "TREATMENT"], [54, 82, "DISEASE"], [88, 98, "TREATMENT"], [12, 20, "PERSON"], [37, 50, "DISEASE"]]}
{"id": 738, "data": "84.", "label": []}
{"id": 744, "data": "1662-1663.", "label": []}
{"id": 750, "data": "a case of interstitial cystitis treated j allergy clin immunol.", "label": [[10, 31, "DISEASE"], [42, 49, "DISEASE"]]}
{"id": 756, "data": "pathogenicity of omalizumab for the treatment of unprovoked anaphylaxis in patients ige in autoimmunity: successful treatment of bullous pemphigoid with with systemic mastocytosis.", "label": [[17, 27, "TREATMENT"], [49, 71, "TREATMENT"], [84, 87, "BIOMARKER"], [129, 147, "DISEASE"], [158, 179, "DISEASE"]]}
{"id": 762, "data": "87.", "label": []}
{"id": 768, "data": "chronic rhinosinusitis.", "label": [[0, 22, "DISEASE"]]}
{"id": 774, "data": "a potential new therapeutic approach for aspirin-exacerbated respiratory 2009;64:1384-1385.", "label": [[41, 72, "TREATMENT"]]}
{"id": 780, "data": "93.", "label": []}
{"id": 786, "data": "incorvaia c, frati f, puccinelli p, riario-sforza gg, dal bo s. dose dependence of efficacy and safety of subcutaneous immunotherapy.", "label": [[0, 11, "PERSON"], [13, 20, "PERSON"], [22, 34, "PERSON"], [36, 52, "PERSON"], [106, 132, "TREATMENT"]]}
{"id": 792, "data": "pediatr allergy immunol.", "label": [[8, 15, "DISEASE"]]}
{"id": 798, "data": "j allergy clin immunol.", "label": [[2, 9, "DISEASE"]]}
{"id": 804, "data": "98.", "label": []}
{"id": 810, "data": "2008;supp! 29:111.", "label": []}
{"id": 816, "data": "2008;18: 225-226.", "label": []}
{"id": 822, "data": "allergol immunopathol (madr).", "label": [[0, 28, "PERSON"]]}
{"id": 828, "data": "shankar t, petrov aa. omalizumab and hypersensitivity reactions.", "label": [[22, 32, "TREATMENT"], [11, 20, "PERSON"], [0, 9, "PERSON"], [37, 53, "DISEASE"]]}
{"id": 840, "data": "ige is also implicated in allergic-bronchopulmonary disease (abpa).", "label": [[0, 3, "BIOMARKER"], [26, 66, "DISEASE"]]}
{"id": 846, "data": "subjects were asked to grade the improvement in their symptom scores on an analogue scale from 0 (no response) to 10 (excellent response).", "label": []}
{"id": 864, "data": "49 were deemed responsive to therapy at 16 weeks whereas 7 did not respond and omalizumab therapy was discontinued.", "label": [[79, 89, "TREATMENT"]]}
{"id": 870, "data": "dosage of omalizumab was as per the manufacturer’s guideline for the primary asthma indication in all 56 patients based on ige levels and weight in kilograms.", "label": [[10, 20, "TREATMENT"], [77, 83, "DISEASE"], [123, 126, "BIOMARKER"]]}
{"id": 882, "data": "the mean ige level pre omalizumab treatment was 346 iu/ml.", "label": [[9, 12, "BIOMARKER"], [23, 33, "TREATMENT"]]}
{"id": 888, "data": "22 out of 37 patients reported a >5 improvement score in their rhino-sinusitis symptoms on omalizumab.", "label": [[91, 101, "TREATMENT"], [63, 87, "DISEASE"]]}
{"id": 894, "data": "figure 3 illustrates the effect of omalizumab on asthmatic symptom score in 4 patients with abpa.", "label": [[35, 45, "TREATMENT"], [49, 72, "DIAGNOSTIC"], [92, 96, "DISEASE"]]}
{"id": 900, "data": "discussion our study has shown that omalizumab is effective in treating concomitant allergic rhinitis and dermatitis in patients with severe allergic asthma in a real observational study.", "label": [[36, 46, "TREATMENT"], [106, 116, "DISEASE"], [72, 101, "DISEASE"], [134, 156, "DISEASE"]]}
{"id": 906, "data": "the major features of anaphylaxis included wheeze, low blood pressure and invariably death.", "label": [[22, 33, "DISEASE"], [51, 69, "DISEASE"], [43, 49, "DISEASE"], [85, 90, "DISEASE"]]}
{"id": 912, "data": "reagin was subsequently isolated as the antibody ige in 1967.(9) furthermore burrows showed in 1989 that most asthmatics and patients with allergic rhinitis had high ige levels when corrected for age and gender.(10) the effectiveness of omalizumab in asthma has proven the concept that ige is centrally pathogenic to this DISEASE.", "label": [[49, 52, "BIOMARKER"], [139, 156, "DISEASE"], [166, 169, "BIOMARKER"], [237, 247, "TREATMENT"], [251, 257, "DISEASE"], [286, 289, "BIOMARKER"], [0, 6, "BIOMARKER"], [77, 84, "PERSON"]]}
{"id": 924, "data": "both allergic rhino-sinusitis and dermatitis appear to have a common ige pathway however there appears to be heterogeneity in their response to treatment.", "label": [[5, 29, "DISEASE"], [34, 44, "DISEASE"], [69, 72, "BIOMARKER"]]}
{"id": 936, "data": "9/37 patients reported no response in their symptoms on omalizumab; 28/37 patients reported an improvement.", "label": [[56, 66, "TREATMENT"]]}
{"id": 942, "data": "patients were asked to grade their symptoms response on a qualitative subjective scale whereby 0 = no response to a maximum response of 10 (excellent response) to omalizumab.", "label": [[163, 173, "TREATMENT"]]}
{"id": 954, "data": "2/4 patients reported a >5 point improvement score in their symptoms on omalizumab.", "label": [[72, 82, "TREATMENT"]]}
{"id": 960, "data": "global strategy for asthma managment and prevention 2014.", "label": [[20, 26, "DISEASE"]]}
{"id": 966, "data": "subramaniam a, al-alawi", "label": [[0, 13, "PERSON"], [15, 23, "PERSON"]]}
{"id": 972, "data": "6.", "label": []}
{"id": 978, "data": "the biology of ige and the basis of allergic disease.", "label": [[15, 18, "BIOMARKER"]]}
{"id": 984, "data": "ige in allergic disease.", "label": [[0, 3, "BIOMARKER"]]}
{"id": 990, "data": "krathen ra, hsu s. failure of omalizumab for treatment of severe adult atopic dermatitis.", "label": [[0, 10, "PERSON"], [30, 40, "TREATMENT"], [12, 17, "PERSON"], [58, 88, "DISEASE"]]}
{"id": 996, "data": "papeojumoq table 1: illustrates the demographics of patients treated with omalizumab for severe asthma with concomitant ige mediated disease.", "label": [[74, 84, "TREATMENT"], [89, 102, "DISEASE"], [108, 140, "DISEASE"]]}
{"id": 1008, "data": "while its safety and efficacy in ciu patients have been evaluated in multiple clinical trials, real-world use of omalizaumab in ciu has not been well characterized.", "label": [[33, 36, "DISEASE"], [113, 124, "TREATMENT"], [128, 131, "DISEASE"]]}
{"id": 1014, "data": "the kaplan-meier method was used to examine omalizumab treatment patterns.", "label": [[4, 16, "PERSON"], [44, 54, "TREATMENT"]]}
{"id": 1020, "data": "conclusions: in this cohort of ciu patients who were newly prescribed omalizumab, the majority were treated by allergists/immunologists as expected, and approximately 60% of patients continued on therapy beyond 18 months.", "label": [[70, 80, "TREATMENT"], [31, 34, "DISEASE"]]}
{"id": 1026, "data": "ear", "label": [[0, 3, "DISEASE"]]}
{"id": 1032, "data": "* long-term real-world data are reported on changes in clinical characteristics and concomitant medication use among ciu patients initiating omalizumab in the united states.", "label": [[141, 151, "TREATMENT"], [117, 120, "DISEASE"]]}
{"id": 1044, "data": "omalizumab, a monoclonal antibody directed against ige,\" was approved in the united states for uncontrolled moderate to severe persistent allergic asthma in 2003 and became a treatment option for ciu after u.s.", "label": [[0, 10, "TREATMENT"], [51, 54, "BIOMARKER"], [138, 153, "DISEASE"], [196, 199, "DISEASE"]]}
{"id": 1050, "data": "postapproval data are only available from a handful of small, short-duration, observational studies, mostly conducted outside the united states.?171° as a result, information on the real-world treatment experience of patients receiving omalizumab for ciu is deficient.", "label": [[236, 246, "TREATMENT"], [251, 254, "DISEASE"]]}
{"id": 1062, "data": "this was defined as >] medical claim for an inpatient stay or emergency department (ed) visit with an international classification of diseases, ninth revision, clinical modification (icd-9-cm) or international classification of diseases, tenth revision, clinical modification (icd-10-cm) diagnosis code for urticaria (icd-9-cm diagnosis codes: 708.xx; icd-10-cm diagnosis codes: l50.0-l50.9) in the primary diagnosis position or with =2 medical claims with distinct service dates for urticaria in any position of the claims in any setting.", "label": [[134, 142, "DISEASE"], [228, 236, "DISEASE"], [307, 316, "DISEASE"], [484, 493, "DISEASE"]]}
{"id": 1080, "data": "the use of medications was evaluated for the baseline period and during the 2 or 3 post-index periods (i.e., 1to 6-month, 7to 12-month, and 13to 18-month follow-up [for patients with >18 months of follow-up]) for first-, second-, and third-line therapies including prescription h1 and h2 antihistamines, montelukast, cyclosporine, oral corticosteroids, hydroxychloroquine, and omalizumab. for omalizumab, usage was reported for continuously treated patients and for those who stopped omalizumab therapy during the 6-, 12-, 18-month, and entire post-index periods (maximum=754 days [-25 months]).", "label": [[11, 22, "TREATMENT"], [285, 302, "TREATMENT"], [304, 315, "TREATMENT"], [317, 329, "TREATMENT"], [331, 351, "TREATMENT"], [377, 387, "TREATMENT"], [393, 403, "TREATMENT"], [484, 494, "TREATMENT"], [278, 280, "TREATMENT"], [353, 371, "TREATMENT"]]}
{"id": 1092, "data": "omalizumab restart from the first discontinuation date until the first restart date or end of study follow-up, whichever occurred first, was also assessed with the kaplan-meier method for the subset of patients who discontinued omalizumab.", "label": [[0, 10, "TREATMENT"], [164, 176, "PERSON"], [228, 238, "TREATMENT"]]}
{"id": 1098, "data": "the 40-64 years age group made up the largest proportion of patients in both the full study population (60.4%) and the subset (60.9%) of patients with > 18 months of followup, as shown in table 1.", "label": []}
{"id": 1104, "data": "(6.7) 14 47) 0.827 0.275 eczema/dermatitis 68 (22.8) 45 (15.1) 38 (12.8) 0.004 <0.001 food allergy 14 (4.7) 9 (©.0) 6 (2.0) 0.166 0.046 angioedema 88 (29.5) 59 (19.8) 39 (13.1) <0.001 <0.001 asthma 77 (25.8) 129 (43.3) 106 (35.6) <0.001 <0.001 copd 3 (1.0) 5 (7) 4 (1.3) 0.157 0.564 anxiety 34 (14) 36 (12.)", "label": [[86, 98, "DISEASE"], [136, 146, "DISEASE"], [191, 197, "DISEASE"], [244, 248, "DISEASE"], [32, 42, "DISEASE"], [25, 31, "DISEASE"], [283, 290, "DISEASE"]]}
{"id": 1110, "data": "(2.0) 4 (13) 0.317 0.655, other specified urticaria 136 (45.6) 125 41.9) 104 (4.9) 0.192 <0.001 urticaria, unspecified 158 (53.0) 117 @g9.3) 91 (0.5) <0.001 <0.001 laboratory tests of interest, n (%) cbc test 144 (48.3) 90 ©@0.2) 95 (31.9) <0.001 <0.001 esr test 90 ©g0.2) 29 (9.7) 36 12.)", "label": [[42, 51, "DISEASE"], [96, 105, "DISEASE"], [200, 208, "DIAGNOSTIC"], [254, 262, "DIAGNOSTIC"]]}
{"id": 1122, "data": "similar trends were observed in patients with >18 months of post-index follow-up and continued over the longer follow-up time period (e.g., months 13-18) as shown in appendix a. www,jmep.org vol.24,no.7 july2018 jmcp journal of managed care & specialty pharmacy 601 real-world characteristics and treatment patterns in patients with urticaria initiating omalizumab in the united states preand post-index concomitant medication use for patients with ciu initiating omalizumab and with > 12 months of follow-up (n=298) 70 621 percentage of patients prescription h1 montelukast antihistamines prescription h2 antihistamines oral corticosteroids cyclosporine hydroxychloroquine concomitant medications 6 months pre-index 6 months post-index 7-12 months post-index @p<0.05 when comparing post-index with pre-index periods.", "label": [[333, 342, "DISEASE"], [354, 364, "TREATMENT"], [464, 474, "TREATMENT"], [575, 605, "TREATMENT"], [606, 620, "TREATMENT"], [621, 654, "TREATMENT"], [686, 697, "TREATMENT"], [449, 452, "DISEASE"], [563, 574, "TREATMENT"], [560, 562, "TREATMENT"], [655, 673, "TREATMENT"]]}
{"id": 1128, "data": "the percentage of patients with a claim for a complete blood count with differential (48.3% vs. 30.2% vs. 31.9%), erythrocyte sedimentation rate (30.2% vs. 9.7% vs. 12.1%), and thyroid antibody test (23.8% vs. 5.7% vs. 5.4%) decreased significantly across the pre-index baseline period and the 1to 6-month and 7to 12-month post-index time periods, respectively (for all comparisons, p<0.001), as shown in table 2.", "label": [[177, 198, "DIAGNOSTIC"], [114, 144, "DIAGNOSTIC"]]}
{"id": 1140, "data": "for patients with >18 months of post-index follow-up, the mean (95% ci) number of days of continuous treatment with omalizumab was 428.4 (400.5-456.4).", "label": [[116, 126, "TREATMENT"]]}
{"id": 1146, "data": "for patients with 212 months of post-index follow-up, 12.1% (n=36), 28.5% (n=85), and 32.9% (n=98) discontinued omalizumab within the 6-month, 12-month, and the entire post-index periods (mean 530 days), respectively.", "label": [[112, 122, "TREATMENT"]]}
{"id": 1152, "data": "24,no.7 july 2018 jmcp journal of managed care & specialty pharmacy 603 real-world characteristics and treatment patterns in patients with urticaria initiating omalizumab in the united states the =>18-month follow-up cohort, the mean (95% ci) number of days from first discontinuation to first restart was 320.5 (282.8-358.1) during the entire post-index period and the probability of restart (95% ci) were 0.301 (0.196-0.444), 0.321 (0.213-0.465), and 0.353 (0.237-0.505) within the 6-, 12-, and 18-month periods since first discontinuation, respectively (data not shown).", "label": [[139, 148, "DISEASE"], [160, 170, "TREATMENT"]]}
{"id": 1164, "data": "in most cases the studies used relatively small sample sizes, had short follow-up periods ranging from 8 weeks to 7 months,*!°?! or were performed outside the united states.", "label": []}
{"id": 1170, "data": "(2015)", "label": []}
{"id": 1176, "data": "ciu patients initiating treatment with omalizumab used significantly fewer other related medications in the post-index period relative to the baseline pre-index period.", "label": [[39, 49, "TREATMENT"], [0, 3, "DISEASE"]]}
{"id": 1188, "data": "604 journal of managed care & specialty pharmacy jcp july 2018 vol.", "label": []}
{"id": 1194, "data": "this was likely mitigated, however, by prior authorization models in the health plans that require the presence of ciu before omalizumab was prescribed.", "label": [[126, 136, "TREATMENT"], [115, 118, "DISEASE"]]}
{"id": 1200, "data": "study patients were identified within administrative claims in one large u.s.based repository and consisted of commercial and medicare advantage health plan enrollees, potentially limiting the generalizability of these results across different populations.", "label": []}
{"id": 1206, "data": "jonathan a. bernstein, md, bernstein clinical research center, cincinnati, ohio, and lisa a. beck, md, university of rochester medical center, rochester, new york.", "label": [[85, 97, "PERSON"], [0, 21, "PERSON"]]}
{"id": 1212, "data": "kavati, ortiz, and paknis are employees of novartis pharmaceuticals.", "label": [[8, 14, "PERSON"], [0, 6, "PERSON"], [19, 25, "PERSON"]]}
{"id": 1218, "data": "acknowledgments b. bernard tulsi, msc, provided writing and editorial support for this project.", "label": [[16, 32, "PERSON"]]}
{"id": 1224, "data": "2.", "label": []}
{"id": 1230, "data": "3.", "label": []}
{"id": 1242, "data": "2014;150(3):288-90. 6.", "label": []}
{"id": 1248, "data": "24,no.7 july2018 jmcp journal of managed care & specialty pharmacy 605 real-world characteristics and treatment patterns in patients with urticaria initiating omalizumab in the united states 7.", "label": [[138, 147, "DISEASE"], [159, 169, "TREATMENT"]]}
{"id": 1254, "data": "j allergy clin immunol.", "label": [[2, 9, "DISEASE"]]}
{"id": 1260, "data": "2016;8(5):396-403.", "label": []}
{"id": 1266, "data": "maurer m, altrichter s, bieber t, et al. efficacy and safety of omalizumab in patients with chronic urticaria who exhibit ige against thyroperoxidase.", "label": [[0, 8, "PERSON"], [10, 22, "PERSON"], [24, 32, "PERSON"], [64, 74, "TREATMENT"], [92, 109, "DISEASE"], [122, 125, "BIOMARKER"], [134, 149, "BIOMARKER"]]}
{"id": 1272, "data": "accessed december 1, 2017.", "label": []}
{"id": 1302, "data": "metz m, ohanyan t, church mk, maurer m. omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.", "label": [[0, 6, "PERSON"], [8, 17, "PERSON"], [19, 28, "PERSON"], [40, 50, "TREATMENT"], [116, 133, "DISEASE"], [30, 38, "PERSON"]]}
{"id": 1308, "data": "2015;33-38. available at: http://www.ajmc.com/ journals/ajac/2015/2015-vol3-n3/applying-weighting-methodologies-to-acommercial-database-to-project-us-census-demographic-data/p-2.", "label": []}
{"id": 1314, "data": "2016;175(2):404-06.", "label": []}
{"id": 1320, "data": "24,no.7 www,jmep.org real-world characteristics and treatment patterns in patients with urticaria initiating omalizumab in the united states lie psa preand post-index clinical characteristics in patients with ciu initiating omalizumab and with >18 months of post-index follow-up (n= 138) 6 months 6 months 7-12 months 13-18 months p value p value p value clinical characteristics pre-index (a) | post-index (b) | post-index (c) | post-index (d) (a vs. b) (a vs. c) (a vs. d) prescribing/treating physician specialty, n (%) 0.384 0.541 0.050 allergist/immunologist 113 (81.9) 117 (84.8) 108 (78.3) 99 (71.7) 0.248 0.251 0.011 dermatologist 8 (5.8) 4 (q9) 6 (4.3) 6 (4.3) 0.102 0.317 0.527 pcp 4 (2.9) 1 (0.7) 3) q.2) 3 (2.2) 0.180 0.705 0.705 others 8 (5.8) 7 gd) 9 (6.5) 8 6.8) 0.655 0.739 1.000 unknown 5 ©g.6) 9 (6.5) 12.", "label": [[88, 97, "DISEASE"], [109, 119, "TREATMENT"], [209, 212, "DISEASE"], [224, 234, "TREATMENT"]]}
{"id": 1332, "data": "0.317 0.317 0.317 dermatographic urticaria 10 (7.2) 3 (2.2) 6 (4.3) 5 (3.6) 0.020 0.248 0.166 vibratory urticaria 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) =", "label": [[18, 42, "DISEASE"], [94, 113, "DISEASE"]]}
{"id": 1338, "data": "all patients had urticaria claims during the study period; however, not all patients had urticaria claims during both the pre-index and post-index periods reported here.", "label": [[17, 26, "DISEASE"], [89, 98, "DISEASE"]]}
{"id": 1344, "data": "ciu = chronic idiopathic urticaria.", "label": [[0, 3, "DISEASE"], [6, 34, "DISEASE"]]}
{"id": 1350, "data": "we report a study of 10 patients with ad (aged 19-35 years) who received anti-ige treatment for persistent asthma.", "label": [[73, 91, "TREATMENT"], [96, 113, "DISEASE"]]}
{"id": 1356, "data": "with the caveats of the financial expense and unknown long-term risks of malignancy associated with omalizumab, this drug should be considered for treatment-resistant patients with ad, particularly patients with high ige level whose symptoms are not controlled by routine therapies.", "label": [[100, 110, "TREATMENT"], [217, 220, "BIOMARKER"], [73, 83, "DISEASE"], [181, 183, "DISEASE"]]}
{"id": 1362, "data": "correspondence: professor beom joon kim, department of dermatology, chung-ang university college of medicine, 224-1 heukseok-dong, dongjak-gu, seoul 156-755, korea e-mail: beomjoon@unitel.co.kr conflict of interest: none declared. accepted for publication 14 march 2012 496 clinical and experimental dermatology (2013) 38, pp496-500 although ad is commonly associated with raised serum ige, the diagnosis of ad is mainly clinical.", "label": [[68, 77, "PERSON"], [116, 129, "PERSON"], [131, 141, "PERSON"], [26, 39, "PERSON"], [342, 344, "DISEASE"], [408, 410, "DISEASE"]]}
{"id": 1368, "data": "therefore, many dermatologists have attempted to treat severe or recalcitrant ad using alternatives such as dapsone, azathioprine, mycophenolate mofetil and intravenous immunoglobulin.", "label": [[108, 115, "TREATMENT"], [117, 129, "TREATMENT"], [157, 183, "TREATMENT"], [65, 80, "DISEASE"], [131, 152, "TREATMENT"]]}
{"id": 1374, "data": "standard therapy (systemic corticosteroids, ciclosporin, ultraviolet radiation) before enrolment.", "label": [[18, 42, "TREATMENT"], [44, 55, "TREATMENT"], [57, 78, "TREATMENT"]]}
{"id": 1380, "data": "all patients had positive results for skin tests or multiple allergosorbent test for common aeroallergens and high ige titres (mainly > 5000 iu/ml) (table 1).", "label": [[115, 118, "BIOMARKER"], [38, 48, "DIAGNOSTIC"], [61, 80, "DIAGNOSTIC"]]}
{"id": 1392, "data": "atopic dermatitis symptoms were baseline", "label": [[0, 26, "DISEASE"]]}
{"id": 1398, "data": "quality of life (qol) was assessed for patients aged > 16 years, using selfadministered questionnaires that incorporated a validated korean version of the dermatology life quality index (dlqi).", "label": [[155, 192, "DIAGNOSTIC"]]}
{"id": 1404, "data": "dloi scores also decreased, from 12.6 + 3.7 at baseline to 6.5 + 3.7 at the end of treatment.", "label": [[0, 11, "DIAGNOSTIC"]]}
{"id": 1410, "data": "figure 2 clinical effect of omalizumab: (a) before treatment with omalizumab, (b) some improvement at the end of 4 months of treatment and (c) significant improvement 2 months after the end of treatment.", "label": [[28, 38, "TREATMENT"], [66, 76, "TREATMENT"]]}
{"id": 1416, "data": "it also downregulates highaffinity ige receptors by binding to and and inactivating ige.”", "label": [[35, 38, "BIOMARKER"], [84, 87, "BIOMARKER"]]}
{"id": 1422, "data": "notably, molecular changes such as a switch to reduced ige/igg mrna production seem to be good indicators of which patients will have clinical response.", "label": [[55, 58, "BIOMARKER"], [59, 67, "BIOMARKER"]]}
{"id": 1434, "data": "the differences in the clinical outcomes may reflect the multifactorial aetiology of ad, with ige as one of several potential mediators.", "label": [[94, 97, "BIOMARKER"], [85, 87, "DISEASE"]]}
{"id": 1440, "data": "omalizumab has proven useful in treating asthma, but the continued exploration of this in the treatment of other DISEASEs, such as allergic rhinitis and ad, may be beneficial, as shown by the present study.", "label": [[0, 10, "TREATMENT"], [41, 47, "DISEASE"], [133, 150, "DISEASE"], [155, 157, "DISEASE"]]}
{"id": 1446, "data": "immunol allergy clin north am 2002; 22: 1-24, 500 clinical and experimental dermatology (2013) 38, pp496-500 2 boguniewicz m, leung d. atopic dermatitis.", "label": [[8, 15, "DISEASE"], [111, 124, "PERSON"], [135, 152, "DISEASE"], [126, 133, "PERSON"]]}
{"id": 1452, "data": "diagnosis and treatment of atopic dermatitis in children and adults: european academy of allergology and clinical immunology/american academy of allergy, asthma and immunology /practall consensus report.", "label": [[27, 44, "DISEASE"], [154, 160, "DISEASE"]]}
{"id": 1458, "data": "7 lowe pj, tannenbaum s&s, gautier a, jimenez", "label": [[2, 9, "PERSON"], [11, 25, "PERSON"], [27, 36, "PERSON"], [38, 45, "PERSON"]]}
{"id": 1470, "data": "e. br j dermatol 1975; 92: 17-25.", "label": []}
{"id": 1476, "data": "the presence of kc was determined by corneal topography read by an ophthalmologist.", "label": [[16, 18, "DISEASE"], [37, 55, "DIAGNOSTIC"]]}
{"id": 1488, "data": "reprints: ayal hassidim, md, israeli defense force medical corps, shiler, 4b jerusalem, israel (e-mail: ayalha@gmail.com).", "label": [[10, 23, "PERSON"]]}
{"id": 1494, "data": "prevalence rate differs geographically with lower rates in other countries such as russia (0.003%)’ and the united states (0.5%).8 the etiology of kc still remains unclear.’", "label": [[147, 149, "DISEASE"]]}
{"id": 1506, "data": "* allergic diseases,'® such as asthma, atopic dermatitis, and allergic rhinitis, are characterized by a hypersensitivity reaction to an allergen.", "label": [[2, 19, "DISEASE"], [31, 37, "DISEASE"], [39, 56, "DISEASE"], [62, 79, "DISEASE"], [104, 120, "DISEASE"]]}
{"id": 1512, "data": "merdler et al allergic inflammation of the ocular surface, involving tarsal and/ or bulbar conjunctiva particularly seen among children and young adults living in regions with hot and dry climate, such as the middle east.", "label": [[0, 7, "PERSON"], [23, 57, "DISEASE"], [84, 102, "DISEASE"]]}
{"id": 1518, "data": "a 7-year, retrospective, observational case-control study by nemet et al,'° published in 2010, examined the association of kc with allergic and autoimmune diseases among 426 patients diagnosed with kc and 1704 ageand gender-matched controls.", "label": [[61, 66, "PERSON"], [131, 163, "DISEASE"], [198, 200, "DISEASE"], [123, 125, "DISEASE"]]}
{"id": 1524, "data": "methods we conducted a cross-sectional study to estimate the epidemiologic relationship between kc and allergic diseases. source of data as a part of the military preconscription assessment, most israeli civilians undergo a routine medical evaluation and fitness-for-service (ffs) classification at a prespecified age.", "label": [[103, 120, "DISEASE"], [96, 98, "DISEASE"]]}
{"id": 1530, "data": "ac, vkc, and chronic blepharitis (cb) are all represented by the same ffs numerical codes in the examinees’ records and therefore were grouped in our analysis as well.", "label": [[13, 37, "DISEASE"], [4, 7, "DISEASE"], [0, 2, "DISEASE"]]}
{"id": 1542, "data": "a multivariate analysis was performed to assess the specific relationship between asthma and kc while neutralizing confounding variables as age, gender, conscription year, and the presence of other allergic DISEASEs.", "label": [[82, 88, "DISEASE"], [93, 95, "DISEASE"]]}
{"id": 1548, "data": "cornea ¢ volume 34, number 5, may 2015 allergic DISEASE in the general population was 15%, which yields a study power of 95.5%.", "label": []}
{"id": 1554, "data": "95% ci: 1.3-2.0; p < 0.001), and the combination of ac/cb/vkc (or: 6.0; 95% ci: 4.0—-9.2; kc and common allergic DISEASEs p < 0.001).", "label": [[52, 54, "DISEASE"], [55, 57, "DISEASE"], [58, 61, "DISEASE"], [90, 92, "DISEASE"]]}
{"id": 1572, "data": "527 copyright © 2015 wolters kluwer health, inc. unauthorized reproduction of this article is prohibited.", "label": []}
{"id": 1578, "data": "its prevalence in the israeli adolescent population, according to our study, is estimated as 0.1% with a slight male predominance (61.5%).", "label": []}
{"id": 1584, "data": "ac, cb, vkc 6.0 4.0-9.2 <0.001 mild* ac, cb, vkc 3.2 1.8-5.8 0.001 severet", "label": [[31, 39, "DISEASE"], [8, 11, "DISEASE"], [4, 6, "DISEASE"], [0, 2, "DISEASE"], [41, 43, "DISEASE"], [45, 48, "DISEASE"]]}
{"id": 1590, "data": "this is especially true regarding ac/ cb/vkc.", "label": [[34, 36, "DISEASE"], [38, 40, "DISEASE"], [41, 44, "DISEASE"]]}
{"id": 1596, "data": "second, the data from this study were retrieved from the ffs codes of the idf.", "label": []}
{"id": 1614, "data": "1995;4: 65-73.", "label": []}
{"id": 1620, "data": "gokhale ns. epidemiology of keratoconus.", "label": [[28, 39, "DISEASE"]]}
{"id": 1632, "data": "kennedy rh, bourne wm, dyer ja.", "label": [[0, 10, "PERSON"], [12, 21, "PERSON"], [23, 30, "PERSON"]]}
{"id": 1638, "data": "10.", "label": []}
{"id": 1650, "data": "2004;29:35—40.", "label": []}
{"id": 1662, "data": "i, duran ja, ruiz c, et al.", "label": [[3, 11, "PERSON"], [13, 19, "PERSON"]]}
{"id": 1674, "data": "2010;29:1261-1264. .", "label": []}
{"id": 1680, "data": "nhis/2012/table2-2.htm.", "label": []}
{"id": 1686, "data": "robbins sl, cotran rm, kumar v, et al. acute and chronic inflammation.", "label": [[0, 10, "PERSON"], [12, 21, "PERSON"], [23, 30, "PERSON"], [49, 69, "DISEASE"]]}
{"id": 1692, "data": "2013;6:370-374.", "label": []}
{"id": 1698, "data": "24.", "label": []}
{"id": 1704, "data": "de souza ga, godoy lm, mann m. identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors.", "label": [[0, 11, "PERSON"], [13, 21, "PERSON"], [23, 29, "PERSON"], [129, 148, "BIOMARKER"]]}
{"id": 1710, "data": "abu el-asrar am, struyf s, al-mosallam aa, et al.", "label": [[27, 41, "PERSON"], [17, 25, "PERSON"], [0, 15, "PERSON"]]}
{"id": 1716, "data": "1997;158:2327-2333.", "label": []}
{"id": 1734, "data": "univariate and multivariable logistic regression models were performed to analyze the independent associations between mild asthma and moderate-to-severe asthma phenotypes and coexistent medical DISEASEs within each gender separately. hierarchical clustering of the odds ratios of the diverse statistically significant medical DISEASEs associated with asthma severity-gender groups was also performed.", "label": [[119, 130, "DISEASE"], [147, 160, "DISEASE"], [356, 362, "DISEASE"]]}
{"id": 1740, "data": "hierarchical clustering analysis uncovered two prominent clusters, separating mild from moderate-tosevere asthma.", "label": [[106, 112, "DISEASE"]]}
{"id": 1746, "data": "it is characterized by intermittent bronchial hyperresponsiveness and reversible airway obstruction, yet presents with multiple clinical forms and levels of severity.", "label": [[36, 65, "DISEASE"], [70, 99, "DISEASE"]]}
{"id": 1752, "data": "inflammatory cells involved in the pathophysiologic pathway, spirometry, airway hyperresponsiveness, exhaled nitric oxide (no) concentration, requirement for medication and type of treatment, persistence of wheezing (treatment responsiveness), triggers and trigger-related phenotypes, healthcare utilization and comorbidities.", "label": [[101, 140, "DIAGNOSTIC"], [73, 99, "DIAGNOSTIC"], [61, 71, "DIAGNOSTIC"], [207, 215, "DISEASE"]]}
{"id": 1758, "data": "increasing attention has been paid in recent years to comorbidities (28-34), including allergic diseases (such as allergic rhinitis, food allergies, hymenoptera sting allergy, atopic dermatitis and atopic skin DISEASEs), migraine (35), attention-deficit/hyperactivity disorder (adhd) and psychogenic disorders (depressive or mood disorders and anxiety).", "label": [[87, 104, "DISEASE"], [114, 131, "DISEASE"], [133, 147, "DISEASE"], [176, 193, "DISEASE"], [149, 174, "DISEASE"], [198, 220, "DISEASE"], [223, 231, "DISEASE"], [238, 285, "DISEASE"], [290, 311, "DISEASE"], [327, 341, "DISEASE"], [346, 353, "DISEASE"]]}
{"id": 1764, "data": "the role of sex hormones, genetic predisposition and comorbidities in airway inflammation, smooth muscle contraction, mucus production and airway mechanics has been demonstrated (43,44). identifying sex-specific risk factors for asthma (45) may have potential diagnostic, therapeutic and prognostic implications.", "label": [[229, 235, "DISEASE"], [118, 134, "DISEASE"], [91, 116, "DISEASE"], [70, 89, "DISEASE"]]}
{"id": 1770, "data": "we also explore the intricate and hierarchical relationships between asthma _ severity, gender and medical signatures.", "label": [[69, 75, "DISEASE"]]}
{"id": 1788, "data": "these correspond to the gina (global initiative for asthma) classifications (1,52) of “intermittent and mild” and “moderate and severe” persistent asthma groupings (http://www.medicalcriteria.com/criteria/pul_asthma.htm), which were the most recent and acceptable criteria at the time of data collection.", "label": [[136, 153, "DISEASE"]]}
{"id": 1794, "data": "as this study aims to investigate the independent associations between comorbidities and the outcome in the two asthma groups (mild or moderate-tosevere) for each gender separately, a three-step process was applied: first, a distinct univariate analysis was conducted for each of the four combinations of clinical asthma group and gender (mild asthma among males, moderate-to-severe asthma among males, mild asthma among were described by proportions 4 y. machluf et al.", "label": [[112, 118, "DISEASE"], [314, 320, "DISEASE"], [339, 350, "DISEASE"], [376, 389, "DISEASE"], [403, 414, "DISEASE"], [456, 463, "PERSON"]]}
{"id": 1806, "data": "clustering analysis hierarchical clustering of the ors of the different medical DISEASEs (only allergic as well as neurological-cognitive-mental disorders were taken into account) and asthma severity-gender groups, was performed with partek® genomics suite” software, version 6.6 copyright ©;", "label": [[186, 192, "DISEASE"]]}
{"id": 1818, "data": "correlates (ors and 95% cls) of mild asthma (a, in males; b, in females) and moderate-to-severe asthma (c, in males; d, in females) with comorbidities in the multivariable logistic regression analysis.", "label": [[32, 43, "DISEASE"], [89, 102, "DISEASE"]]}
{"id": 1824, "data": "learning disabilities and add/adhd were only associated with the moderate-to-severe form of asthma but not with mild asthma, in both males and females (figure 1).", "label": [[92, 98, "DISEASE"], [112, 123, "DISEASE"], [26, 29, "DISEASE"], [30, 34, "DISEASE"]]}
{"id": 1842, "data": "in addition, female gender, above normal body mass index (bmi) and hypertension are all associated with increased risk of developing moderate-to-severe asthma, whereas family related variables (eldest child and bigger family size) display a protective effect.", "label": [[145, 158, "DISEASE"]]}
{"id": 1848, "data": "other objective evidence including exhaled no and methacholine bronchial challenge, was collected in some subjects and we moderate-severe asthma vs. mild asthma journal of asthma 7 socio-demographic variables gender: female education: 12+ years family size: > 3 siblings eldest child (2.12-2.75 [0.99-1.32 [0.75-0.98 [0.73-0.96 above normal bmi pre-hypertensior hypertension i+ll anthropometric indices [1.06-1.44 (0.99-1.29 [0.37-0.66 neumothorax lactase deficiency migraine epilepsy anxiety-mood disorder learning disabilities add/adhd other comorbidities [1.05-10.3 1.49 [1.03-2.16]", "label": [[131, 144, "DISEASE"], [149, 160, "DISEASE"], [172, 178, "DISEASE"], [35, 45, "DIAGNOSTIC"], [50, 82, "DIAGNOSTIC"], [380, 402, "DIAGNOSTIC"], [448, 466, "DISEASE"], [467, 475, "DISEASE"], [476, 484, "DISEASE"], [485, 506, "DISEASE"], [529, 537, "DISEASE"], [507, 528, "DISEASE"], [436, 447, "DISEASE"], [328, 344, "DISEASE"], [345, 379, "DISEASE"]]}
{"id": 1854, "data": "correlates (ors and 95% cls) of moderate-to-severe asthma vs. mild asthma in the multivariable logistic regression analysis.", "label": [[44, 57, "DISEASE"], [62, 73, "DISEASE"]]}
{"id": 1860, "data": "cross-sectional surveys and small cohorts support the relationship of asthma with diverse comorbidities including: upper airway diseases (rhinitis - usually allergic, sinusitis and rhinosinusitis), neurologic disorders (learning disorders - mainly adhd, migraine and epilepsy) and psychological dysfunction (depression, anxiety, mood and behavioral disorders), gerd and other gastrointestinal (gi) diseases (dyspepsia), laryngeal dysfunction (mainly paradoxical vocal fold movement), pulmonary and _ bronchial diseases (chronic obstructive lung disease, bronchiectasis, bronchitis, bronchopneumonia, recurrent respiratory infections), atherosclerotic cardiac disease and circulatory disorders, dermatologic DISEASEs (eczema/psoriasis), connective tissue/rheumatic diseases, metabolic disorders and hormonal imbalance, immunologic and hematologic disease, obesity, sleep apnea and chronic pain DISEASEs (24,28-31).", "label": [[70, 76, "DISEASE"], [115, 136, "DISEASE"], [138, 146, "DISEASE"], [254, 262, "DISEASE"], [267, 275, "DISEASE"], [320, 327, "DISEASE"], [361, 365, "DISEASE"], [500, 518, "DISEASE"], [520, 552, "DISEASE"], [570, 580, "DISEASE"], [600, 633, "DISEASE"], [671, 692, "DISEASE"], [719, 725, "DISEASE"], [756, 774, "DISEASE"], [776, 795, "DISEASE"], [857, 864, "DISEASE"], [882, 905, "DISEASE"], [167, 176, "DISEASE"], [181, 195, "DISEASE"], [248, 252, "DISEASE"], [308, 318, "DISEASE"], [338, 358, "DISEASE"], [198, 218, "DISEASE"], [220, 238, "DISEASE"], [376, 406, "DISEASE"], [408, 417, "DISEASE"], [420, 441, "DISEASE"], [450, 481, "DISEASE"], [554, 568, "DISEASE"], [582, 598, "DISEASE"], [635, 666, "DISEASE"], [694, 717, "DISEASE"], [726, 735, "DISEASE"], [738, 755, "DISEASE"], [836, 855, "DISEASE"], [820, 831, "DISEASE"], [800, 818, "DISEASE"], [866, 877, "DISEASE"]]}
{"id": 1866, "data": "this study aimed to shed light on the coexistence of medical DISEASEs with asthma severity phenotypes among adolescent males and females.", "label": [[77, 83, "DISEASE"]]}
{"id": 1872, "data": "it also brought to light associations of lactase deficiency and hypertension with development of moderate-to-severe asthma.", "label": [[41, 59, "DISEASE"], [109, 122, "DISEASE"], [64, 76, "DISEASE"]]}
{"id": 1878, "data": "this may be due to the burden of their medical DISEASE and may reflect the negative impact of asthma on neurobehavioral health.", "label": [[96, 102, "DISEASE"]]}
{"id": 1890, "data": "not only was drug treatment for asthma, allergic rhinitis and atopic dermatitis more common among adhd subjects, but also medication prescription for asthma and allergic rhinitis among parents was associated with adhd treatment in their children (63).", "label": [[32, 38, "DISEASE"], [40, 57, "DISEASE"], [62, 79, "DISEASE"], [98, 102, "DISEASE"], [150, 156, "DISEASE"], [161, 178, "DISEASE"], [213, 217, "DISEASE"]]}
{"id": 1896, "data": "better characterization of asthma phenotypes is required, from both an etiological and clinical perspective.", "label": [[27, 33, "DISEASE"]]}
{"id": 1902, "data": "the limitations of this study include being restricted to one recruitment center and to a certain age group, an under-representation of certain populations (such as minorities and religious women that are exempt from service), lack of additional background information on socio-demographic and lifestyle factors (socio-economic status (ses) and smoking habits) and genetic information.", "label": []}
{"id": 1908, "data": "future attempts to profile the “medical signature” of asthmatic adolescents should use parallel protocols among children and adults (males and females separately), as well as longitudinally follow the progression journal of asthma 9 of such profiles over time.", "label": [[224, 230, "DISEASE"]]}
{"id": 1920, "data": "2.", "label": []}
{"id": 1926, "data": "bateman ed, jithoo a. asthma and allergy - a global perspective.", "label": [[0, 10, "PERSON"], [22, 28, "DISEASE"], [33, 40, "DISEASE"], [12, 20, "PERSON"]]}
{"id": 1932, "data": "mechanisms of immune regulation in allergic diseases: the role of regulatory t and b cells.", "label": [[35, 52, "DISEASE"], [83, 90, "BIOMARKER"]]}
{"id": 1938, "data": "i. the interplay between neuroendocrine activity and psychological stress-induced exacerbation of allergic asthma.", "label": [[98, 113, "DISEASE"]]}
{"id": 1944, "data": "drugs 2014;74: 719-728.", "label": []}
{"id": 1950, "data": "11.", "label": []}
{"id": 1956, "data": "chung kf, wenzel se, brozek jl, bush a, castro m, sterk pj, adcock im, bateman ed, bel eh, bleecker er, et al.", "label": [[0, 8, "PERSON"], [10, 19, "PERSON"], [21, 30, "PERSON"], [32, 38, "PERSON"], [40, 48, "PERSON"], [50, 58, "PERSON"], [60, 69, "PERSON"], [71, 81, "PERSON"], [83, 89, "PERSON"], [91, 102, "PERSON"]]}
{"id": 1962, "data": "teague wg, meyers da, peters sp, li x, li h, wenzel se, aujla s, castro m, bacharier lb, et al.", "label": [[0, 9, "PERSON"], [11, 20, "PERSON"], [22, 31, "PERSON"], [33, 37, "PERSON"], [39, 43, "PERSON"], [45, 54, "PERSON"], [56, 63, "PERSON"], [65, 73, "PERSON"], [75, 87, "PERSON"]]}
{"id": 1968, "data": "haldar p, pavord id, shaw de, berry ma, thomas m, brightling ce, wardlaw aj, green rh. cluster analysis and clinical asthma phenotypes.", "label": [[0, 8, "PERSON"], [10, 19, "PERSON"], [21, 28, "PERSON"], [30, 38, "PERSON"], [40, 48, "PERSON"], [50, 63, "PERSON"], [65, 75, "PERSON"], [77, 85, "PERSON"], [117, 123, "DISEASE"]]}
{"id": 1974, "data": "j allergy clin immunol 2010;126:519-526 el-7.", "label": [[2, 9, "DISEASE"]]}
{"id": 1992, "data": "e, lee sh, kwon", "label": [[3, 9, "PERSON"]]}
{"id": 2016, "data": "23.", "label": []}
{"id": 2034, "data": "doi: 10.1183/13993003.00284-2015.", "label": []}
{"id": 2040, "data": "erj open res 2018;4.", "label": []}
{"id": 2046, "data": "clin exp allergy 2010;40:1130-1141.", "label": [[9, 16, "DISEASE"]]}
{"id": 2064, "data": "thorax 2010; 65:612-618.", "label": []}
{"id": 2070, "data": "epub 2009/12/10.", "label": []}
{"id": 2082, "data": "asthma-related comorbidities.", "label": [[0, 6, "DISEASE"]]}
{"id": 2094, "data": "42.", "label": []}
{"id": 2100, "data": "ullmann n, mirra v, di marco a, pavone m, porcaro f, negro v, onofri a, cutrera r. asthma: differential diagnosis and comorbidities. front pediatr 2018;6:276.", "label": [[0, 9, "PERSON"], [11, 18, "PERSON"], [20, 30, "PERSON"], [32, 40, "PERSON"], [42, 51, "PERSON"], [53, 60, "PERSON"], [62, 70, "PERSON"], [83, 89, "DISEASE"], [72, 82, "PERSON"]]}
{"id": 2106, "data": "epub 2017/11/28.", "label": []}
{"id": 2112, "data": "in: huang k-hg, ed. asthma diagnosis and management.", "label": [[20, 26, "DISEASE"], [4, 14, "PERSON"]]}
{"id": 2118, "data": "labor m, labor §, juric i, fijacko v, grle sp, plavec d. mood disorders in adult asthma phenotypes.", "label": [[27, 36, "PERSON"], [38, 45, "PERSON"], [57, 71, "DISEASE"], [75, 87, "DISEASE"], [18, 25, "PERSON"], [47, 56, "PERSON"]]}
{"id": 2124, "data": "epub 2015/06/20.", "label": []}
{"id": 2130, "data": "fischer gb, sarria ee, mattiello r, mocelin ht, castro-rodriguez ja. post infectious bronchiolitis obliterans in children.", "label": [[0, 10, "PERSON"], [12, 21, "PERSON"], [23, 34, "PERSON"], [36, 46, "PERSON"], [48, 67, "PERSON"], [74, 98, "DISEASE"]]}
{"id": 2142, "data": "pediatr pulmonol 2003;36:22-26.", "label": []}
{"id": 2154, "data": "tse sm, rifas-shiman sl, coull ba, litonjua aa, oken e, gold dr. sex-specific risk factors for childhood wheeze and longitudinal phenotypes of wheeze.", "label": [[0, 6, "PERSON"], [8, 23, "PERSON"], [25, 33, "PERSON"], [35, 46, "PERSON"], [48, 54, "PERSON"], [56, 63, "PERSON"], [105, 111, "DISEASE"], [143, 149, "DISEASE"]]}
{"id": 2160, "data": "51.", "label": []}
{"id": 2178, "data": "epub 2010/ 09/18.", "label": []}
{"id": 2184, "data": "epub 2013/01/02.", "label": []}
{"id": 2196, "data": "three phenotypes of adult-onset asthma.", "label": [[32, 38, "DISEASE"]]}
{"id": 2202, "data": "ann am thorac soc 2013;10:s118-s124.", "label": []}
{"id": 2208, "data": "jw, huang kl, chang wh, chen tj, bai ym.", "label": [[4, 12, "PERSON"], [14, 22, "PERSON"], [24, 31, "PERSON"], [33, 39, "PERSON"]]}
{"id": 2214, "data": "56.", "label": []}
{"id": 2220, "data": "57.", "label": []}
{"id": 2226, "data": "58.", "label": []}
{"id": 2232, "data": "chatzikonstantinou a. epilepsy and the hippocampus. front neurol neurosci 2014;34:121-142.", "label": [[22, 30, "DISEASE"]]}
{"id": 2250, "data": "epub 2014/08/19.", "label": []}
{"id": 2256, "data": "epub 2016/06/19.", "label": []}
{"id": 2274, "data": "allergies allergic conjunctivitis diagnosis was made according to previous documentation, a history of redness of conjunctiva, edema, itching and lacrimation associated with season and/or allergens and verified by an eye specialist.", "label": [[0, 9, "DISEASE"], [114, 125, "DISEASE"], [127, 132, "DISEASE"], [10, 33, "DISEASE"], [134, 141, "DISEASE"], [146, 157, "DISEASE"]]}
{"id": 2280, "data": "urticaria and angioedema/food allergies diagnosis was made according to previous documentation and characteristic history of typical general skin rash (hives) for urticaria, general swelling including swelling of the neck, face, tongue and larynx for angioedema, specific skin tests and ige levels for specific foods allergy, verified by a specialist in allergy.", "label": [[0, 9, "DISEASE"], [14, 24, "DISEASE"], [25, 39, "DISEASE"], [141, 150, "DISEASE"], [163, 172, "DISEASE"], [272, 282, "DIAGNOSTIC"], [287, 290, "BIOMARKER"], [311, 324, "DISEASE"], [354, 361, "DISEASE"], [152, 157, "DISEASE"], [201, 246, "DISEASE"], [251, 261, "DISEASE"]]}
{"id": 2286, "data": "in this analysis, only severe add/adhd was included, requiring daily consumption of medication (ritalin or concerta).", "label": [[34, 38, "DISEASE"], [30, 33, "DISEASE"], [96, 103, "TREATMENT"], [107, 115, "TREATMENT"]]}
{"id": 2292, "data": "lactase deficiency lactase deficiency was diagnosed by a certified gastroenterologist relying on medical history and laboratory workup.", "label": [[0, 18, "DISEASE"], [19, 37, "DISEASE"]]}
{"id": 2298, "data": "autoimmune connective tissue diseases this group of diseases included rheumatoid arthritis, systemic lupus erythematosus, sjogren disease, scleroderma, mixed connective tissue disease, polymyositis dermatomyositis and psoriatic arthritis.", "label": [[70, 90, "DISEASE"], [0, 37, "DISEASE"], [92, 120, "DISEASE"], [122, 137, "DISEASE"], [139, 150, "DISEASE"], [152, 183, "DISEASE"], [185, 213, "DISEASE"], [218, 237, "DISEASE"]]}
{"id": 2304, "data": "hoarseness hoarseness was diagnosed according to examination and previous documentation and was substantiated by a certified ent specialist following examination of the larynx and pharynx for possible pathologies.", "label": [[11, 21, "DISEASE"], [0, 10, "DISEASE"], [150, 187, "DIAGNOSTIC"]]}
{"id": 2310, "data": "the actual definitions were as follows: obesity - above the 95th percentile (>28.2 and >", "label": [[40, 47, "DISEASE"]]}
{"id": 2322, "data": "appendix b description of univariate analysis findings associations in males of the medical DISEASEs, 12 DISEASEs were associated with either mild asthma or moderate-to-severe asthma - all associated with a higher risk among the asthmatic male populations (compared with the corresponding non-asthmatic ones).", "label": [[146, 157, "DISEASE"], [173, 186, "DISEASE"]]}
{"id": 2328, "data": "du doyen gaston giraud, 34295 montpellier cedex 5, tel : +33630061134, fax : +33467330740, e-mail : davide.caimmi @", "label": [[9, 23, "PERSON"], [0, 8, "PERSON"]]}
{"id": 2334, "data": "d. phenotypical characterization of children with hypersensitivity reactions to nsaids pediatr allergy immunol background.", "label": [[50, 66, "DISEASE"], [80, 86, "TREATMENT"], [95, 102, "DISEASE"]]}
{"id": 2346, "data": "on the basis of our results, we are proposing an adapted classification for nsaids hypersensitivity in children.", "label": [[76, 99, "DISEASE"]]}
{"id": 2352, "data": "introduction non-steroidal anti-inflammatory drugs (nsaids) are widely used to treat fever and pain in children.", "label": [[52, 58, "TREATMENT"], [13, 50, "TREATMENT"], [85, 90, "DISEASE"], [95, 99, "DISEASE"]]}
{"id": 2358, "data": "in 2001, stevenson classified patients according to their clinical history but this classification did not take into account the reactions recorded during drug provocation tests (dpts)", "label": [[9, 18, "PERSON"], [155, 184, "DIAGNOSTIC"]]}
{"id": 2364, "data": "since its publication, clinical observations and literature data (6) reported that some patients diagnosed with nsaids hs could not be classified into the possible phenotypes described by the enda group (5).", "label": [[112, 121, "DISEASE"]]}
{"id": 2370, "data": "we also tried to identify possible risk factors for nsaids hs in children, and to propose a pediatric version of the enda classification.", "label": [[52, 61, "DISEASE"]]}
{"id": 2376, "data": "patients on bblockers were asked to visit their specialist to stop the drug 2 days prior to the test.", "label": [[12, 21, "TREATMENT"]]}
{"id": 2382, "data": "we excluded all patients who had experienced severe life-threatening skin reactions (toxic epidermal necrolysis and stevens johnson syndrome), drug-induced autoimmune diseases or severe organ involvements (such as cytopenias, hepatitis, dress-drug reaction with eosinophilia and systemic symptoms), since dpts are contra-indicated for such reactions.", "label": [[45, 83, "DISEASE"], [156, 175, "DISEASE"], [179, 204, "DISEASE"], [214, 224, "DISEASE"], [262, 274, "BIOMARKER"], [85, 111, "DISEASE"], [116, 140, "DISEASE"], [226, 235, "DISEASE"]]}
{"id": 2388, "data": "we tested children with the culprit drug and, in case of a positive dpt, patients were tested, at least 4 weeks after the previous dpt, with a different nsaid, belonging to another chemical subgroup. all together, 14 different nsaids have been tested, belonging to this article is protected by copyright.", "label": [[153, 158, "TREATMENT"], [227, 233, "TREATMENT"]]}
{"id": 2394, "data": "nsaids-exacerbated cutaneous disease 3.", "label": [[0, 36, "DISEASE"]]}
{"id": 2400, "data": "a multivariate analysis was conducted using a logistic regression model to determine independent risk factors of nsaids, in which we included all variables associated with a p value below 0.20 in the univariate analysis.", "label": [[113, 119, "TREATMENT"]]}
{"id": 142447, "data": "After omalizumab treatment for 35 days, the UAS score decreased to under 15  in all of the BAT-negative patients, whereas in 6 out of the 13 BAT-positive patients, the scores remained over 16 .", "label": [[6, 26, "TREATMENT"], [44, 53, "BIOMARKER"]]}
{"id": 142448, "data": "Clinical evaluation, microscopic assessment and the detection of autoantibodies are helpful, but not specific.", "label": [[21, 43, "DIAGNOSTIC"], [52, 79, "DIAGNOSTIC"]]}
{"id": 142449, "data": "Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA LEN taskforce position paper.", "label": [[108, 117, "DISEASE"]]}
{"id": 142450, "data": "The presence of angioedema has frequently a negative impact on QoL due to pain or alteration of the physical aspect related to oedema .", "label": [[16, 26, "DISEASE"], [127, 133, "DISEASE"]]}
{"id": 142451, "data": "The prevalence of HLA-DPB1*0301, which is a significant gene marker of NERD, did not significantly differ among the 4 subtypes, suggesting that serum periostin and HLA-DPB1*0301 may not be biomarkers differentiating the 4 subtypes of NERD.", "label": [[18, 31, "BIOMARKER"], [144, 159, "BIOMARKER"], [164, 177, "BIOMARKER"], [71, 75, "DISEASE"], [234, 238, "DISEASE"]]}
{"id": 142452, "data": "Analysis of convergent validity To determine the convergent validity of both UAS7 instruments, we correlated  their values with those of the above-mentioned anchors of disease activity , disease control , and HRQOL .", "label": [[77, 93, "DIAGNOSTIC"]]}
{"id": 142454, "data": "Objectives We sought to investigate the profile of expression of activation markers on basophils of patients with CIU and to explore the effect of interleukin -3 priming upon anti-IgE cross-linking stimuli through expression of activation markers and basophil histamine releasability.", "label": [[87, 96, "BIOMARKER"], [147, 161, "BIOMARKER"], [175, 183, "BIOMARKER"], [251, 259, "BIOMARKER"], [260, 269, "BIOMARKER"], [114, 117, "DISEASE"]]}
{"id": 142456, "data": "In this respect, CU is also characterized by elevated vascular endothelial growth factor, one of the major mediators of vascular permeability, expressed by skin eosinophils, which parallels disease severity and is associ-ated with plasma levels of fragment F112 and, hence, with the ac-tivation of the coagulation cascade.", "label": [[54, 88, "BIOMARKER"], [248, 261, "BIOMARKER"], [302, 321, "BIOMARKER"], [17, 19, "DISEASE"], [120, 141, "BIOMARKER"], [156, 172, "BIOMARKER"]]}
{"id": 142457, "data": "SEE PROFILE Per S Skov University of Southern Denmark 365 PUBLICATIONS9,566 CITATIONS SEE PROFILE All content following this page was uploaded by Edward Knol on 04 July 2019.", "label": [[146, 157, "PERSON"]]}
{"id": 142458, "data": "Associations with coexistent medical conditions In order to investigate the independent associations between comorbidities and anthropometric indices and the outcome in the two asthma groups  separately within genders, analy-ses were conducted to compare each of the four cate-gories  with its corresponding reference group .", "label": [[109, 122, "DISEASE"], [177, 183, "DISEASE"]]}
{"id": 142459, "data": "Neutrophils were analyzed in gate 1, monocytes were analyzed in gate 2, NK cells, B cells, and T cells were analyzed in gate 3, and basophils were analyzed in gate 4.", "label": [[0, 11, "BIOMARKER"], [37, 46, "BIOMARKER"], [72, 80, "BIOMARKER"], [82, 89, "BIOMARKER"], [95, 102, "BIOMARKER"], [132, 141, "BIOMARKER"]]}
{"id": 142460, "data": "f007a006f d f006b d e d006f006b a f e a f c d e b00e a f c e f3006b d e> /ITA  /JPN <FEFF30d330b830cd30b", "label": [[10, 21, "BIOMARKER"], [57, 60, "BIOMARKER"], [68, 71, "BIOMARKER"]]}
{"id": 142461, "data": "Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria.", "label": [[41, 53, "BIOMARKER"], [68, 77, "BIOMARKER"], [89, 106, "DISEASE"]]}
{"id": 142462, "data": "Error bars represent 95% confidence intervals of proportion, calculated with n = number of surface IgE-positive cells.", "label": [[99, 117, "BIOMARKER"]]}
{"id": 142463, "data": "Activation of mast cells induced by agonists of proteinase-activated receptors under normal conditions and during acute inflammation in rats.", "label": [[14, 24, "BIOMARKER"], [114, 132, "DISEASE"], [48, 78, "BIOMARKER"]]}
{"id": 142464, "data": "These data revealed that either serum total IgE or eosinophilia can affect the S. aureus colonization as shown in Table 3, and these two parameters showed additive effects on S. aureus coloni-zation in chronic skin lesions of AD patients.", "label": [[32, 47, "BIOMARKER"], [51, 63, "BIOMARKER"], [202, 222, "DISEASE"], [226, 228, "DISEASE"], [79, 101, "BIOMARKER"], [175, 198, "BIOMARKER"]]}
{"id": 142465, "data": "The insufficient effect of H1-antihistamine in some patients with chronic spontaneous urticaria  suggests that factors other than histamine are involved in the patho-physiology of CSU.", "label": [[27, 43, "TREATMENT"], [66, 95, "DISEASE"], [180, 183, "DISEASE"], [130, 139, "BIOMARKER"]]}
{"id": 142466, "data": "Antibodies, which are produced by the associated B cells and helper T cells, may play an important role in the pathogenesis of urticaria .", "label": [[49, 56, "BIOMARKER"], [68, 75, "BIOMARKER"], [127, 136, "DISEASE"]]}
{"id": 142467, "data": "Patients who required frequent pulsed courses of corticosteroids or on immunosuppressive agents to control the urticaria were excluded from the study.", "label": [[49, 64, "TREATMENT"], [71, 95, "TREATMENT"], [111, 120, "DISEASE"]]}
{"id": 142468, "data": "Bossi F, Frossi B, Radillo O, Cugno M, Tedeschi A, Riboldi P, Asero R, Tedesco F, Pucillo C. Mast cells 195 are critically involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity 196 IgE receptor stimulation.", "label": [[170, 187, "DISEASE"], [213, 237, "BIOMARKER"], [0, 7, "PERSON"], [9, 17, "PERSON"], [19, 28, "PERSON"], [30, 37, "PERSON"], [39, 49, "PERSON"], [51, 60, "PERSON"], [62, 69, "PERSON"], [71, 80, "PERSON"], [82, 91, "PERSON"], [93, 103, "BIOMARKER"], [135, 166, "BIOMARKER"]]}
{"id": 142469, "data": "The most common adverse effects were headache, nausea, dysphonia, fatigue, weight gain and paresthesia.", "label": [[37, 45, "DISEASE"], [47, 53, "DISEASE"], [55, 64, "DISEASE"], [66, 73, "DISEASE"], [75, 86, "DISEASE"], [91, 102, "DISEASE"]]}
{"id": 142470, "data": "Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD: Efficacy and safety of a recombinant anti-immunoglobulin E antibody  in severe allergic asthma.", "label": [[81, 93, "PERSON"], [163, 184, "BIOMARKER"], [198, 220, "DISEASE"], [0, 10, "PERSON"], [12, 24, "PERSON"], [26, 34, "PERSON"], [36, 45, "PERSON"], [47, 57, "PERSON"], [59, 67, "PERSON"], [69, 79, "PERSON"], [95, 100, "PERSON"], [102, 113, "PERSON"], [115, 124, "PERSON"]]}
{"id": 142471, "data": "J ALLERGY CLIN IMMUNOL PRACT VOLUME-, NUMBER- ODA ETAL 10.e7 Low Responsiveness of Basophils via FcRI Reflects Disease Activity in Chronic Spontaneous Urticaria Materials and Methods Study population Basophil activation test Measurement of IgE and FcRI levels on basophils Autologous serum skin test Statistical analysis Results Study population Measurement of CD203c expression after FcRI stimulation on basophils in patients with CSU Measurement of IgE and FcRI levels on basophils of patients with CSU IgE and FcRI levels on basophils in patients with CSU were not strongly correlated with CD203c expression Classification of patients with CSU according to basophil CD203c reactivity Discussion Acknowledgments References Online Repository", "label": [[97, 101, "BIOMARKER"], [240, 243, "BIOMARKER"], [248, 259, "BIOMARKER"], [263, 272, "BIOMARKER"], [361, 367, "BIOMARKER"], [405, 414, "BIOMARKER"], [432, 435, "DISEASE"], [451, 454, "BIOMARKER"], [459, 470, "BIOMARKER"], [474, 483, "BIOMARKER"], [513, 524, "BIOMARKER"], [528, 537, "BIOMARKER"], [555, 558, "DISEASE"], [593, 599, "BIOMARKER"], [643, 646, "DISEASE"], [660, 675, "BIOMARKER"], [131, 160, "DISEASE"], [200, 224, "DIAGNOSTIC"], [273, 299, "DIAGNOSTIC"], [385, 389, "BIOMARKER"], [501, 504, "DISEASE"], [505, 508, "BIOMARKER"], [83, 92, "BIOMARKER"]]}
{"id": 142472, "data": "Administration of ketoconazole or erythromycin at the same time increases bilastine area under the curve  and Cmax, whilst diltiazem increases the drug plasma concentration.", "label": [[18, 30, "TREATMENT"], [34, 46, "TREATMENT"], [123, 132, "TREATMENT"], [74, 88, "BIOMARKER"]]}
{"id": 142473, "data": "Conversely, a predictor with an HR significantly greater than 1 would be indicative of attenuated duration of CIU.", "label": [[110, 113, "DISEASE"]]}
{"id": 142474, "data": "The mean TSS value decreased by 81% at the end of therapy with respect to the baseline evaluation in the group treated with levocetirizine, and by 1% in the group treated with placebo.", "label": [[9, 12, "BIOMARKER"], [124, 138, "TREATMENT"], [176, 183, "TREATMENT"]]}
{"id": 142475, "data": "Also in support of the latter possibility is the likelihood that endothelial cells in CSU may be activated by autoantibodies, cytokines, comple-ment, histamine and other mast cell-derived factors; this process may be responsible for TF expression, and secondary extrinsic coagulation pathway activation and fibrinolysis.9 In line with endothelial cell activation in CSU, Puxeddu et al. have recently detected that biomarkers of endothe-lium dysfunction  were increased in a large number of patients with CSU, in addition to other chemokines  that contribute to the amplification of the inflammatory process during the late phase of urticaria.", "label": [[86, 89, "DISEASE"], [126, 135, "BIOMARKER"], [150, 159, "BIOMARKER"], [170, 195, "BIOMARKER"], [366, 369, "DISEASE"], [504, 507, "DISEASE"], [632, 641, "DISEASE"], [65, 82, "BIOMARKER"], [137, 148, "BIOMARKER"], [335, 362, "BIOMARKER"], [371, 378, "PERSON"], [428, 452, "BIOMARKER"]]}
{"id": 142476, "data": "M. L. A. Schutte- laar, R. A. Tupker, Thomas Rustemeyer, Phyllis Spuls and Roy Gerth van Wijk in the Netherlands; Drs.", "label": [[0, 22, "PERSON"], [24, 36, "PERSON"], [38, 55, "PERSON"], [57, 70, "PERSON"], [75, 93, "PERSON"]]}
{"id": 142477, "data": "serum skin test vs autologous plasma skin test in patients with chronic urticaria: ity, quality of life and anti-thyroid antibodies.", "label": [[64, 81, "DISEASE"], [108, 131, "BIOMARKER"], [0, 15, "DIAGNOSTIC"], [19, 46, "DIAGNOSTIC"]]}
{"id": 142478, "data": "Hide M, Hiragun T, Japanese Dermatological A. Japanese guidelines for diagnosis and treatment of urticaria in comparison with other countries.", "label": [[97, 106, "DISEASE"], [0, 6, "PERSON"], [8, 17, "PERSON"]]}
{"id": 142479, "data": "Transsignaling in Chronic Spontaneous Urticaria PLOS ONE | December 23, 2015 7 / 9 CSU patients show significant increase not only in plasma IL-6 and IL-6 sR concentrations, but also in sgp130, which acts as a negative regulator of IL-6 trans-signaling.", "label": [[83, 86, "DISEASE"], [141, 145, "BIOMARKER"], [150, 154, "BIOMARKER"], [155, 172, "BIOMARKER"], [186, 192, "BIOMARKER"], [232, 236, "BIOMARKER"], [18, 47, "DISEASE"]]}
{"id": 142480, "data": "Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M. Severe chronic urticaria is associated with elevated plasma levels of D-dimer.", "label": [[134, 141, "BIOMARKER"], [9, 19, "PERSON"], [0, 7, "PERSON"], [21, 30, "PERSON"], [32, 42, "PERSON"], [44, 53, "PERSON"], [55, 62, "PERSON"], [64, 88, "DISEASE"]]}
{"id": 142481, "data": "The maximum UAS for wheals was signifi-cantly higher for individuals with chronic urticaria than for those with acute ur-ticaria , but there was no significant difference for pruritus .", "label": [[12, 15, "BIOMARKER"], [74, 91, "DISEASE"], [112, 128, "DISEASE"], [175, 183, "DISEASE"], [20, 26, "DISEASE"]]}
{"id": 142483, "data": "Thus our results may contribute to the literature revealing that psycho-logical factors play an important role in the attacks and frequency of exacerbations of urticaria.", "label": [[160, 169, "DISEASE"]]}
{"id": 142484, "data": "The majority of patients sample analyzed present-ed mild urticaria activity with low quality of life impairment.", "label": [[57, 66, "DISEASE"]]}
{"id": 142485, "data": "By definition acute urticaria lasts no longer than six weeks, whereas chronic urticaria lasts longer, often several years.", "label": [[14, 29, "DISEASE"], [70, 87, "DISEASE"]]}
{"id": 142487, "data": "Seven out of 48 patients had systemic involvement and ASST positivity was seen in five out of those seven patients.", "label": [[54, 69, "BIOMARKER"]]}
{"id": 142490, "data": "1255 Turkish Journal of Medical Sciences Turk J Med Sci  48: 1255-1262 TBTAK doi:10.3906/sag-1803-87 Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria Ragp ERTA1,*, Kemal ZYURT1, idem KARAKK2, Muhammet Reat AKKU1, Emin ZL3, Atl AVCI1, Mustafa ATASOY1 1Department of Dermatology and Venereology, Health Sciences University, Kayseri Health Training and Research Center, Kayseri, Turkey 2Department of Biochemistry, Health Sciences University, Kayseri Health Training and Research Center, Kayseri, Turkey 3Department of Dermatology and Venereology, Faculty of Medicine, Dzce University, Dzce, Turkey * Correspondence: 1.", "label": [[115, 134, "BIOMARKER"], [174, 184, "TREATMENT"], [139, 166, "BIOMARKER"], [212, 248, "DISEASE"]]}
{"id": 142491, "data": "To assess demographics, clinical characteristics, and treat-ment patterns of CIU patients who initiated omalizumab to better under-stand the usage of this agent in CIU management in the real world.", "label": [[104, 114, "TREATMENT"], [164, 167, "DISEASE"]]}
{"id": 142492, "data": "Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M. Severe chronic urticaria is associated with elevated plasma levels of D-dimer.", "label": [[134, 141, "BIOMARKER"], [9, 19, "PERSON"], [21, 30, "PERSON"], [32, 42, "PERSON"], [44, 53, "PERSON"], [55, 62, "PERSON"], [0, 7, "PERSON"], [64, 88, "DISEASE"]]}
{"id": 142493, "data": "Similarly, Deza et al23 showed that a higher rate of positive Autologous Serum Skin Test  was associated with insufficient thera-peutic effect.", "label": [[62, 88, "DIAGNOSTIC"], [11, 15, "PERSON"]]}
{"id": 142494, "data": "Keywords Autologous serum skin test Allergy Asthma IL-18 Urticaria Introduction Chronic urticaria , recurrent hives lasting more than 6 weeks, remains one of the diseases with unexplained pathogenetic mechanism in spite of recent developments.", "label": [[51, 66, "DISEASE"], [80, 97, "DISEASE"], [100, 115, "DISEASE"], [9, 35, "DIAGNOSTIC"], [36, 43, "DISEASE"], [44, 50, "DISEASE"]]}
{"id": 142495, "data": "We can disrupt mast cell activation by targeting the main mast cell- activating signal, IgE.8 IgE-induced mast cell activation is one of the crucial links between the cause and the symptoms of CSU, and anti-IgE therapy has dramatically improved the treatment of patients with long-term, refractory", "label": [[15, 24, "BIOMARKER"], [94, 105, "BIOMARKER"], [193, 196, "DISEASE"], [106, 126, "BIOMARKER"], [202, 218, "TREATMENT"]]}
{"id": 142496, "data": "showing that there were no statistically significant difference between ASST and the urticaria severity score.", "label": [[72, 76, "DISEASE"], [85, 94, "DISEASE"]]}
{"id": 142497, "data": "Monthly monitoring included blood pressure, urinalysis, and blood work to evaluate liver function, serum creatinine, blood counts, and cyclosporine trough levels.", "label": [[28, 42, "BIOMARKER"], [44, 54, "BIOMARKER"], [83, 97, "BIOMARKER"], [99, 115, "BIOMARKER"], [117, 129, "BIOMARKER"], [60, 70, "BIOMARKER"], [135, 161, "BIOMARKER"]]}
{"id": 142498, "data": "In general, the peak incidence of CU is observed between 20 and 40 years of age.3,13,18 The mean age of CU patients was 41.6 years in Korea from 2010 to 2014 in the present study.", "label": [[34, 36, "DISEASE"], [104, 106, "DISEASE"]]}
{"id": 142499, "data": "Platzer, M.H.; Grattan, C.E.; Poulsen, L.K.; Skov, P.S. Validation of basophil histamine release against the autologous serum skin test and outcome of serum-induced basophil histamine release studies in a large population of chronic urticaria patients.", "label": [[70, 88, "DIAGNOSTIC"], [165, 173, "BIOMARKER"], [225, 242, "DISEASE"], [0, 12, "PERSON"], [15, 27, "PERSON"], [30, 42, "PERSON"], [45, 54, "PERSON"], [109, 135, "DIAGNOSTIC"]]}
{"id": 142500, "data": "We first examined the expression of the two classes of low-affinity IgG receptors, FcRII and FcRIII, on basophils and, as positive and negative controls, on other white blood cells.", "label": [[68, 81, "BIOMARKER"], [83, 88, "BIOMARKER"], [93, 99, "BIOMARKER"], [104, 113, "BIOMARKER"], [163, 180, "BIOMARKER"]]}
{"id": 142501, "data": "Clinical observation indeed suggests additional mechanisms of action, since omalizumab has frequently displayed a very rapid onset of action , full activity well beyond the half-life of the drug and/or at suboptimal doses for IgE neutralisation, and, finally, no inhibition of mast cell degranulation in vivo .", "label": [[76, 86, "TREATMENT"], [226, 244, "BIOMARKER"], [277, 300, "BIOMARKER"]]}
{"id": 142504, "data": "For the 98 patients who discontinued omalizumab during the entire post-index period, 28.6% restarted omalizumab after the first discontinuation within the post-index period .", "label": [[37, 47, "TREATMENT"], [101, 111, "TREATMENT"]]}
{"id": 142505, "data": "Nearly 10% of patients were receiving first generation H1-antihistamines, which are not recommended for the treatment of CU.", "label": [[55, 72, "TREATMENT"], [121, 123, "DISEASE"]]}
{"id": 142506, "data": "Previous publications showed that AE most often occurred within the first month of ACEI treatment and ~27% of cases occurred after more than 6 months after treatment initiation .", "label": [[83, 97, "TREATMENT"]]}
{"id": 142508, "data": "We retrospectively reviewed the medical records and compared the duration of treatment and step of medications using the urticaria control test .", "label": [[121, 130, "DISEASE"]]}
{"id": 142509, "data": "Chronic urticaria most commonly affects women in between their 30s and 40s, a time during which childbearing can be a consideration, but the effect of omalizumab on chronic urticaria in women who are trying to conceive, pregnant or nursing has not been studied in clinical trials.", "label": [[0, 17, "DISEASE"], [151, 161, "TREATMENT"], [165, 182, "DISEASE"]]}
{"id": 142510, "data": "There were no statistically significant tion was significantly longer and accompanying angioedema was lower in patients ) who has been using omalizumab at the beginning of study has been included for Fig.", "label": [[87, 97, "DISEASE"], [141, 151, "TREATMENT"]]}
{"id": 142511, "data": "The TSS is based on the total of individual, patient assessed symptom scores for itching and number of wheals for 208 patients in a 6-week, randomised, double-blind, multicentre trial.", "label": [[81, 88, "DISEASE"], [103, 109, "DISEASE"], [4, 7, "DIAGNOSTIC"]]}
{"id": 142512, "data": "The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.", "label": [[46, 77, "DISEASE"]]}
{"id": 142513, "data": "Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli E. Luquin*, A. P. Kaplanw and M. Ferrer*", "label": [[28, 37, "BIOMARKER"], [55, 72, "DISEASE"], [150, 159, "BIOMARKER"], [177, 194, "DISEASE"], [244, 253, "PERSON"], [256, 269, "PERSON"], [274, 283, "PERSON"]]}
{"id": 142515, "data": "The aim of the study was to evaluate children with urticaria and define risk factors for requirement of high-dose H1-antihistamines in children with urticaria.", "label": [[51, 60, "DISEASE"], [114, 131, "TREATMENT"], [149, 158, "DISEASE"]]}
{"id": 142517, "data": "It also should be noted that the treatment in our present study followed Korean Expert Opinion Report on the Management of CU, not international guidelines.6 Despite these limitations, we provide useful in-formation regarding the natural course of CU in children, the response rates to medical treatment, and prognostic factors.", "label": [[123, 125, "DISEASE"], [248, 250, "DISEASE"]]}
{"id": 142518, "data": "Patients were regarded unresponsive to sgAHs when they chose answer options 1 and/or 2 for all 3 questions.", "label": [[39, 44, "TREATMENT"]]}
{"id": 142519, "data": "bOverall, 388  patients reported using high dose, 381  patients reported using low dose, and/or 97  patients reported using unknown doses or as needed doses of second generation H1-antihistamines.", "label": [[178, 195, "TREATMENT"]]}
{"id": 142520, "data": "There-fore, a two-step model is likely to operate in this setting, where basophils get first activated by cross-linking of IgE on = error of 14 ears of 9 Mcpt8Cre mice and 7 ears of 5 WT mice from two experiments.", "label": [[73, 82, "BIOMARKER"], [123, 126, "BIOMARKER"]]}
{"id": 142522, "data": "317 Summary Abstract Fexofenadine, the active metabolite of terfenadine, is a selective histamine H1 receptor antagonist that does not cross the blood brain barrier and appears to display some anti-inflammatory properties.", "label": [[60, 71, "TREATMENT"], [98, 120, "TREATMENT"], [21, 33, "TREATMENT"]]}
{"id": 142523, "data": "It is prevalent in approximately 0.08% to 0.5% of the population and predominately affects women.1e5,10e12 Different studies have investigated the underlying biologic mechanisms and management of CIU/CSU,13,14 but few have lsevier Inc.", "label": [[196, 203, "DISEASE"]]}
{"id": 142524, "data": "Timing and duration of omalizumab response in patients with 300 Dermatol Ther   8: chronic idiopathic/spontaneous urticaria.", "label": [[23, 33, "TREATMENT"], [83, 123, "DISEASE"]]}
{"id": 142525, "data": "Basophil histamine release activity and disease severity in chronic idiopathic urticaria Basophil histamine release activity and disease severity in chronic idiopathic urticaria Rosalyn Baker, MD, MHS*; Kavitha Vasagar, MS*; Nkiruka Ohameje, MD, MPH*; Laura Gober, MD*; Suephy C. Chen, MD, MS; Patricia M. Sterba, BS*; and Sarbjit S. Saini, MD* Background:", "label": [[60, 88, "DISEASE"], [149, 177, "DISEASE"], [0, 35, "BIOMARKER"], [89, 124, "BIOMARKER"], [178, 191, "PERSON"], [203, 218, "PERSON"], [225, 240, "PERSON"], [252, 263, "PERSON"], [270, 284, "PERSON"], [294, 312, "PERSON"], [323, 339, "PERSON"]]}
{"id": 142526, "data": "The effect of fexofenadine hydrochloride on produc-tivity and quality of life in patients with chronic idiopathic urticaria.", "label": [[14, 40, "TREATMENT"], [95, 123, "DISEASE"]]}
{"id": 142527, "data": "Th2 polarity with excess production of Th2 cytokines  may be a key factor in the epithelial production of fibronectin and fibrinogen, which can act as substrates for S. aureus adherence9.", "label": [[39, 52, "BIOMARKER"], [106, 117, "BIOMARKER"], [122, 132, "BIOMARKER"]]}
{"id": 142529, "data": "2018 British Association of Dermatologists British Journal of Dermatology  180, pp5666 Omalizumab in patients with antihistamine-resistant CSU, Berard et al.", "label": [[87, 97, "TREATMENT"], [115, 142, "DISEASE"], [144, 150, "PERSON"]]}
{"id": 142530, "data": "Correspondence: Dr Marta Ferrer, Department of Allergy and Clinical Immunology, Clinica Universitaria, Aptdo 4209, -Pamplona, Spain.", "label": [[47, 54, "DISEASE"], [16, 31, "PERSON"]]}
{"id": 142531, "data": "Bruno G, Andreozzi P, Graf U. Exercise-induced urticaria-angioedema syndrome: a role in gastroesophageal reflux.", "label": [[0, 7, "PERSON"], [9, 20, "PERSON"], [22, 28, "PERSON"], [47, 56, "DISEASE"], [57, 67, "DISEASE"], [88, 111, "DISEASE"]]}
{"id": 142532, "data": "One pathway is by the activation of Th17 cells and the second by the induction of the secretion of IL-17 by non-T cells.14,44", "label": [[36, 46, "BIOMARKER"], [99, 104, "BIOMARKER"]]}
{"id": 142533, "data": "156 Authors reply S. Pradeep Nair.............................................................................................................................................................", "label": [[18, 28, "PERSON"]]}
{"id": 142534, "data": "This high rate of sgAH-resistant CholU patients, which is in line with previous reports from specialized urti-caria centers , is likely to have patients and physicians often turn to older fgAH and corticosteroids, which are still held by many to be more effective than sgAH despite the fact that several studies have shown that fgAH have far more and more pronounced side effects than sgAH .", "label": [[197, 212, "TREATMENT"], [188, 192, "TREATMENT"], [269, 273, "TREATMENT"], [328, 332, "TREATMENT"], [385, 389, "TREATMENT"]]}
{"id": 142535, "data": "Metz M, Krull C, Maurer M. Histamine, TNF, C5a, IL-6,-9,-18, -31,-33, TSLP, neopterin, and VEGF are not elevated in chronic spontaneous urticaria.", "label": [[38, 41, "BIOMARKER"], [43, 46, "BIOMARKER"], [70, 74, "BIOMARKER"], [76, 85, "BIOMARKER"], [116, 145, "DISEASE"], [8, 15, "PERSON"], [17, 25, "PERSON"], [0, 6, "PERSON"], [48, 68, "BIOMARKER"], [91, 95, "BIOMARKER"]]}
{"id": 142536, "data": "Levels of FcRI+ and IgE+ cells in omalizumab-treated patients at Week 12 had reduced to levels of those seen in healthy subjects at baseline.", "label": [[10, 15, "BIOMARKER"], [20, 30, "BIOMARKER"]]}
{"id": 142537, "data": "There was an equal distribution of males and females with positive FcR1 autoantibodies and posi-tive ASST results.", "label": [[67, 71, "BIOMARKER"], [101, 105, "DISEASE"]]}
{"id": 142538, "data": "Concentration of this cytokine in mild CU grup did not differ significantly as compared with the healthy subject .", "label": [[34, 41, "DISEASE"], [22, 30, "BIOMARKER"]]}
{"id": 142539, "data": "Over-all, patients with CIU have a significant disease burden independent of their basophil phenotype.", "label": [[24, 27, "DISEASE"], [83, 101, "BIOMARKER"]]}
{"id": 142540, "data": "The Italian Medical Agency  restricts the prescription of omalizumab  only to CSU patients with inadequate response to treatment with antihistamines.", "label": [[58, 68, "TREATMENT"], [78, 81, "DISEASE"], [134, 148, "TREATMENT"]]}
{"id": 142541, "data": "This is a longer period comparing with published data from the literature, reporting that ACEI-AE can appear from few hours up to 8 years after ACEI therapy initiation .", "label": [[144, 148, "TREATMENT"], [90, 97, "DISEASE"]]}
{"id": 142542, "data": "Acknowledgments The authors would like to acknowledge former Novartis employee Janice Canvin for her invaluable contributions to the study design, data collection, and analysis, and interpretation of the results.", "label": [[79, 92, "PERSON"]]}
{"id": 142543, "data": "However, the high effi-cacy of omalizumab in various types of urticaria has not been fully elucidated.", "label": [[31, 41, "TREATMENT"], [62, 71, "DISEASE"]]}
{"id": 142544, "data": "so lo ne 20 m g/ kg /d ay 10 10 N /A 10 0 10 0 10 0 10 0 10 0 10 0 Factors Predicting the Response to Cyclosporin St ud y", "label": [[102, 113, "TREATMENT"]]}
{"id": 142545, "data": "At Month 24, spontaneous remission had occurred in nearly 20% of CSU patients, and only 1.5% of CSU pa-tients had relapsed after spontaneous remission.", "label": [[65, 68, "DISEASE"], [96, 99, "DISEASE"]]}
{"id": 142546, "data": "As evidenced by a recent real-world systematic review of omalizumab for CU, most studies originate from developed countries in Europe and the United States, where omalizumab is readily available for physicians to use, and it is usually reimbursed by health insurance.6 In contrast, in Latin America, economic and health insurance limitations appear to in-fluence the prescription of omalizumab to a greater extent.", "label": [[57, 67, "TREATMENT"], [72, 74, "DISEASE"], [163, 173, "TREATMENT"], [383, 393, "TREATMENT"]]}
{"id": 142548, "data": "Although first-generation H 1-antihis-tamines are used to calm children down and to make them sleep better, there is evidence that these agents may also lead to paradoxical central excitation, restlessness, insomnia or seizures in some patients .", "label": [[193, 205, "DISEASE"], [207, 215, "DISEASE"], [161, 191, "DISEASE"], [219, 227, "DISEASE"]]}
{"id": 142549, "data": "The search strategy combined the following terms: Autologous serum skin test and chronic spontaneous urticaria.", "label": [[50, 76, "DIAGNOSTIC"], [81, 110, "DISEASE"]]}
{"id": 142550, "data": "One microgram of total RNA was used for the synthesis of 20 ll of complementary DNA  by Super Script II First-Strand Synthesis System for RT-PCR .", "label": [[80, 83, "BIOMARKER"]]}
{"id": 142551, "data": "Because mast cell activation by anti-Fc RI from some CU patients has been shown to be impaired when IgE is bound to its high-affi nity receptor , we screened ASST+ and ASST patients for total serum IgE levels.", "label": [[8, 17, "BIOMARKER"], [32, 42, "BIOMARKER"], [53, 55, "DISEASE"], [100, 103, "BIOMARKER"], [168, 172, "DISEASE"], [158, 163, "DISEASE"], [192, 208, "BIOMARKER"]]}
{"id": 142552, "data": "All rights reserved. | 3 such as cyclosporine and/or antileukotrienes and/or systemic steroids and/or omalizumab, was prescribed to control their urticaria symptoms.", "label": [[33, 45, "TREATMENT"], [53, 69, "TREATMENT"], [77, 94, "TREATMENT"], [102, 112, "TREATMENT"], [146, 155, "DISEASE"]]}
{"id": 142553, "data": "This altered feedback could cause CIU and other organs damage by means of immuno-tolerance alteration.", "label": [[34, 37, "DISEASE"]]}
{"id": 142554, "data": "Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria.", "label": [[7, 16, "BIOMARKER"], [88, 105, "DISEASE"], [58, 84, "BIOMARKER"]]}
{"id": 142555, "data": "In a study by Staubach et al, 23 AST treatment led to improved disease symptoms and its severity, as well as improved level of quality of life.", "label": [[14, 22, "PERSON"], [33, 36, "TREATMENT"]]}
{"id": 142557, "data": "A short course of glucocorticosteroids may be considered in case of severe exacerbations.2,4 Omalizumab is one of the oldest biologics, and received approval for the treatment of allergic asthma in 2003.", "label": [[18, 38, "TREATMENT"], [93, 103, "TREATMENT"], [179, 194, "DISEASE"]]}
{"id": 142558, "data": "Other authors have demonstrated autoantibodies against ENA, cardiolipin, 2-glycoprotein, rheumatoid factor, endothelial cell and myeloperoxidase in chronic urticaria patients .", "label": [[55, 58, "BIOMARKER"], [108, 124, "BIOMARKER"], [129, 144, "BIOMARKER"], [148, 165, "DISEASE"], [60, 71, "BIOMARKER"], [73, 87, "BIOMARKER"], [89, 106, "BIOMARKER"]]}
{"id": 142559, "data": "Asero R, Marzano AV, Ferrucci S, Cugno M. D-Dimer Plasma Levels Parallel the Clinical Response 411 to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria.", "label": [[0, 7, "PERSON"], [42, 56, "BIOMARKER"], [102, 112, "TREATMENT"], [130, 166, "DISEASE"], [9, 19, "PERSON"], [21, 31, "PERSON"], [33, 40, "PERSON"]]}
{"id": 142560, "data": "Another impediment is the lack of laboratory indicators that would make the diagnosis of NSAID hy-persensitivity easier.", "label": [[89, 94, "TREATMENT"]]}
{"id": 142562, "data": "It has been shown to be effective in reducing hospital admissions, adverse effects and symptom scores in severe asthma.", "label": [[105, 118, "DISEASE"]]}
{"id": 142563, "data": "Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course randomized, placebo-controlled and double-blind pilot study.", "label": [[49, 59, "TREATMENT"], [71, 88, "DISEASE"], [103, 106, "BIOMARKER"], [9, 17, "PERSON"], [19, 26, "PERSON"], [28, 37, "PERSON"], [39, 47, "PERSON"], [0, 7, "PERSON"]]}
{"id": 142564, "data": "Submucosal tunneling endo-scopic resection vs thoracoscopic enucleation for large submuco-sal tumors in the esophagus and the esophagogastric junction.", "label": [[46, 71, "TREATMENT"], [0, 42, "TREATMENT"], [94, 100, "DISEASE"]]}
{"id": 142565, "data": "The number of prescription fills as well as the highest step of the CIU/CSU step- 1 claim with a diagnosis for idiopathic, other or unspecified urticaria1 n = 634,848 Diagnosed CIU/CSU based on algorithm2: either 2 independent claims with a diagnosis for idiopathic, other or unspecified urticaria 6 weeks apart, or 1 claim with a diagnosis for urticaria and 1 claim with a diagnosis for angioedema 6 weeks apart1,3 n = 91,996  1 omalizumab pharmacy or medical claim with the first claim  being after March 21, 2014 n = 4,582  12 months of eligibility prior to the index date n = 3,370  12 months of eligibility after the index date n = 1,560  12 years of age at the index date n = 1,546", "label": [[177, 184, "DISEASE"], [288, 297, "DISEASE"], [345, 354, "DISEASE"], [388, 398, "DISEASE"], [430, 440, "TREATMENT"], [68, 75, "DISEASE"]]}
{"id": 142566, "data": "Antihistamines do not inhibit the wheal induced by the intradermal injection of autologous serum in resistant chronic idiopathic urticaria.", "label": [[0, 14, "TREATMENT"], [110, 138, "DISEASE"], [34, 39, "DISEASE"], [80, 96, "TREATMENT"]]}
{"id": 142567, "data": "Changes in clinical efficacy, as measured by the weekly ISS, correlated weakly with changes in histamine concentration  as well as changes in basophil percentage .", "label": [[142, 161, "DIAGNOSTIC"], [56, 59, "DIAGNOSTIC"], [95, 104, "BIOMARKER"]]}
{"id": 142568, "data": "The UAS7  is a validated patient report outcome including two parameters number of wheals  and intensity of itch .", "label": [[83, 89, "DISEASE"], [108, 112, "DISEASE"]]}
{"id": 142569, "data": "In contrast, it was reported that CD63-based basophil releasability by IL-3 coincubation after stimulation with anti-IgE antibody was decreased after omalizumab treatment compared with baseline values.21 Many reports have described pretreatment biomarkers to predict the efficacy of omalizumab in CSU.", "label": [[45, 67, "DIAGNOSTIC"], [71, 75, "BIOMARKER"], [112, 120, "BIOMARKER"], [150, 160, "TREATMENT"], [283, 293, "TREATMENT"], [297, 300, "DISEASE"]]}
{"id": 142570, "data": "It presents as chronic spontaneous urticaria , chronic inducible urticaria  or both in the same person.", "label": [[15, 44, "DISEASE"], [47, 74, "DISEASE"]]}
{"id": 142572, "data": "Sys- tematic review: psychological morbidity in young people with inflam- matory bowel disease risk factors and impacts.", "label": [[81, 94, "DISEASE"]]}
{"id": 142574, "data": "The first classifica-tion of hypersensitivity to NSAIDs presented by Steven-son et al. in 2001 was based on clinical symptoms, the presence of chronic disease, and cross-reactivity with other COX-1 inhibitors.", "label": [[29, 45, "DISEASE"], [49, 55, "TREATMENT"], [192, 208, "BIOMARKER"]]}
{"id": 142575, "data": "Objective: Optimization of the basophil activation test to detect autoreactive serum components in patients with CU.", "label": [[113, 115, "DISEASE"], [31, 55, "DIAGNOSTIC"]]}
{"id": 142577, "data": "No statistically significant differences were noted in the duration of disease, duration of papules, interval between attacks, and the association of angioedema between the patients .", "label": [[150, 160, "DISEASE"], [92, 99, "DISEASE"]]}
{"id": 142580, "data": "In addition, C3 levels were found to be significantly higher in patients with CSU with metabolic syndrome and were positively correlated with a CSU severity score.21", "label": [[13, 22, "BIOMARKER"], [78, 81, "DISEASE"], [87, 105, "DISEASE"], [144, 162, "DIAGNOSTIC"]]}
{"id": 142581, "data": "In conclusion, the results of our single-institution case series attest to the real-world safety and efficacy of omalizumab in severe refractory CSU.", "label": [[113, 123, "TREATMENT"], [127, 148, "DISEASE"]]}
{"id": 142582, "data": "timulation index , defined as the ratio between the ercentage of degranulated donor basophils  fter stimulation with a patients serum and the percentage f activated basophils without stimulation , was calculated for each patient.", "label": [[84, 93, "BIOMARKER"], [165, 174, "BIOMARKER"]]}
{"id": 142583, "data": "Not only was drug treatment for asthma, allergic rhinitis and atopic dermatitis more common among ADHD subjects, but also medication prescription for asthma and allergic rhinitis among parents was associated with ADHD treatment in their children .", "label": [[32, 38, "DISEASE"], [40, 57, "DISEASE"], [62, 79, "DISEASE"], [150, 156, "DISEASE"], [161, 178, "DISEASE"], [98, 102, "DISEASE"], [213, 217, "DISEASE"]]}
{"id": 142584, "data": "Kaplan, A. P., Joseph, K., Maykut, R. J., Geba, G. P. & Zeldin, R. K. Treatment of chronic autoimmune urticaria with omalizumab.", "label": [[83, 111, "DISEASE"], [117, 127, "TREATMENT"], [56, 69, "PERSON"], [42, 53, "PERSON"], [27, 40, "PERSON"], [15, 25, "PERSON"], [0, 13, "PERSON"]]}
{"id": 142585, "data": "Our study demonstrated a relatively higher frequency of CAU patients  and also ASST  and APST positivity  compared to previous literature .", "label": [[56, 59, "DISEASE"], [79, 83, "DISEASE"], [89, 93, "DISEASE"]]}
{"id": 142586, "data": "A B 9 h O Reprints: Karina Raimundo, BParm, MS, Genent Francisco, CA ; E-mail: Disclosure: Drs Broder, Chang, and Cherepanov, an Partnership for Health Analytic Research, LLC, a h paid to conduct this research.", "label": [[20, 35, "PERSON"], [48, 64, "PERSON"], [95, 101, "PERSON"], [103, 108, "PERSON"], [114, 124, "PERSON"]]}
{"id": 142589, "data": "Cells are activated as a result of receptor cross-linking , and histamine release is augmented by activation of complement to release C5a .", "label": [[64, 73, "BIOMARKER"], [134, 137, "BIOMARKER"]]}
{"id": 142590, "data": "Basophils of CIU pa-tients with a responder phenotype had reduced Src-homology 2containing5-inositol phospha- tase 1 protein levels, an inhibitor in the FcRI histamine degranulation pathway.23", "label": [[0, 9, "BIOMARKER"], [13, 16, "DISEASE"], [153, 167, "BIOMARKER"]]}
{"id": 142591, "data": "UCT score,14 mean SD, median 4.8 3.3, 4.5  11.1 4.1, 12  6.4 4.2, 6  CU-Q2oL total score, 13 mean SD, median 52.8 18.5, 53.3  25.5 18.7, 23.9  26.5 19.9, 23.9  DLQI score,15 mean SD, median 13.1 6.9, 12  5.2 5.6, 3.5  7.6 6.4, 7  TABLE II.", "label": [[69, 71, "DISEASE"], [0, 9, "DIAGNOSTIC"]]}
{"id": 142592, "data": "This change in CU management is supported by the increased risk of infection that comes with these therapies, both showing strong and non-selective immunosuppressive effects .", "label": [[15, 17, "DISEASE"]]}
{"id": 142593, "data": "Apparently, CU is associated with a specific pattern of comorbidities, including autoimmune, atopic and psychiatric diseases and there is no clear pattern in relation to malignant and cardiovascular diseases .", "label": [[12, 14, "DISEASE"]]}
{"id": 142594, "data": "For the 43 patients who stopped omalizumab treatment and did not restart during the observation period for remission of symptoms, nine patients  were treated with omalizumab for less than 6 months and 34 patients  were treated longer than 6 months.", "label": [[32, 42, "TREATMENT"], [163, 173, "TREATMENT"]]}
{"id": 142595, "data": "MacGlashan DW Jr. Releasability of human basophils: cellular sensitivity and maximal histamine release are independent variables.", "label": [[85, 102, "DIAGNOSTIC"]]}
{"id": 142596, "data": "We investigated 80 children referred to the Allergy and Dermatology Clinic of the Red Cross Childrens Hospital, Cape Town, South Africa, for evaluation of CU.", "label": [[155, 157, "DISEASE"]]}
{"id": 142597, "data": "Basophil pheno-types in chronic idiopathic urticaria in relation to disease activ-ity and autoantibodies.", "label": [[24, 52, "DISEASE"], [0, 8, "BIOMARKER"]]}
{"id": 142598, "data": "Taken together, modern second-generation antihista- mines should be considered as the first-line symptomatic treatment for urticaria because of their good safety profile.", "label": [[123, 132, "DISEASE"]]}
{"id": 142599, "data": "Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology The Korean Academy of Pediatric Allergy and Respiratory Disease438 INTRODUCTION", "label": [[32, 38, "DISEASE"], [40, 47, "DISEASE"], [104, 111, "DISEASE"]]}
{"id": 142600, "data": "Other clinical endpoints also showed improvements, including the physicians and patients global assessment scores, itch and hives assessment scores, percentage of angioedema-free days and use of rescue medication.", "label": [[124, 147, "DIAGNOSTIC"]]}
{"id": 142601, "data": "Individuals 15 years of age who met the diagnostic criteria of CSU, having recurrent wheals and flare of less than 24 hours occurring at least 2 times per week for 6 weeks without identifiable causes, were enrolled in the study.", "label": [[63, 66, "DISEASE"], [85, 91, "DISEASE"], [96, 101, "DISEASE"]]}
{"id": 142603, "data": "The diminished patients antioxidant capacities at baseline are likely to be a consequence of a prolonged reactive oxygen species generation due to chronic inflammation.", "label": [[147, 167, "DISEASE"]]}